Cover Page  for Protocol  
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED]  
Sponsor t rial ID:  NN1436 -4481  
Official title of study:  Effectiveness and safety of once weekly insulin icodec used 
with DoseGuide versus once daily basal insulin analogues in 
an insulin naïve type 2 diabetes population in a clinical 
practice setting  (ONWARDS 5 ) 
Document date *: 23 November 2020  
 
*Document date refers to the date on which the document was most recently updated.  
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  1 of 89 
 
   
 Protocol  
 
Effectiveness and safety of once weekly insulin icodec used with DoseGuide 
versus once daily basal insulin analogues in an insulin naïve type 2 diabetes 
population in a clinical practice setting  
ONWARDS 5  
Substance: Insulin icodec  
Universal Trial Number: U1111 -[ADDRESS_927084] Number: 2020 -000476 -38  
IND Number:137406  
 
 
Trial phase:  3a 
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.  
                
                 
 
 
  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.[ADDRESS_927085] be restricted to relevant 
parties.
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  2 of 89 
 
   
 Protocol amendment summary of changes table  
DOCUMENT HISTORY  
Document version  Date  Applicable in country( -ies) 
and/or site(s)  
Protocol version 2.0  23 November 2020  All countries  
Original protocol version 1.0  12 November 2020  All countries  
 
Overall rationale for preparing protocol, version 2.0: 
Section # and name  [CONTACT_18054] 10.3.[ADDRESS_927086] reporting.  
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 2 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  3 of 89 
 
   
 Table of Contents    
 ................................ ................................ ................................ ................................ ........................  Page  
Table of Contents ................................ ................................ ................................ ................................ ..............  2 
1 Protocol summary  ................................ ................................ ................................ ................................ ..... 7 
1.1 Synopsis  ................................ ................................ ................................ ................................ ...........  7 
1.2 Flowchart  ................................ ................................ ................................ ................................ ....... 10 
2 Introduction  ................................ ................................ ................................ ................................ .............  12 
2.1 Trial rationale  ................................ ................................ ................................ ................................ . 12 
2.2 Background  ................................ ................................ ................................ ................................ .... 12 
2.3 Benefit -risk a ssessment  ................................ ................................ ................................ ..................  14 
2.3.1  Risk assessment  ................................ ................................ ................................ ...............  14 
2.3.2  Benefit assessment  ................................ ................................ ................................ ...........  17 
2.3.3  Overall benefit -risk conclusion  ................................ ................................ .......................  18 
3 Objectives and endpoints  ................................ ................................ ................................ ........................  18 
3.1 Primary, secondary and exploratory objective and estimand ................................ .........................  18 
3.1.1  Primary objective  ................................ ................................ ................................ .............  18 
3.1.2  Secondary objective  ................................ ................................ ................................ .........  18 
3.2 Prim ary, secondary and exploratory endpoints  ................................ ................................ ..............  19 
3.2.1  Primary endpoint  ................................ ................................ ................................ .............  19 
3.2.2  Secondary endpoints  ................................ ................................ ................................ ........  19 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ ..... 19 
3.2.3  Exploratory endpoints  ................................ ................................ ................................ ..... 20 
4 Trial design  ................................ ................................ ................................ ................................ ..............  20 
4.1 Overall design  ................................ ................................ ................................ ................................  20 
4.2 Scientific  rationale for trial design  ................................ ................................ ................................ . 22 
4.3 Justification for dose  ................................ ................................ ................................ ......................  23 
4.4 End of trial definition  ................................ ................................ ................................ .....................  23 
5 Trial population  ................................ ................................ ................................ ................................ ....... 23 
5.1 Inclusion criteria  ................................ ................................ ................................ ............................  24 
5.2 Exclusion criteria  ................................ ................................ ................................ ...........................  24 
5.3 Lifestyle considerations  ................................ ................................ ................................ .................  25 
5.3.1  Meals and dietary restrictions  ................................ ................................ ..........................  25 
5.3.2  Caffeine, alcohol and tobacco  ................................ ................................ .........................  25 
5.4 Screen failures  ................................ ................................ ................................ ................................  25 
5.5 Run-in criteria, randomisation criteria and dosing day criteria ................................ ......................  25 
6 Treatments  ................................ ................................ ................................ ................................ ...............  25 
6.1 Treatments administered  ................................ ................................ ................................ ................  25 
6.1.1  Medical devices  ................................ ................................ ................................ ...............  27 
[IP_ADDRESS]  Investigational medical device  ................................ ................................ ........  27 
[IP_ADDRESS]  Non-investigational medical device  ................................ ................................  28 
6.2 Preparation/handling/storage/accountability  ................................ ................................ ..................  28 
6.3 Measures to minimise bias: Randomisation and blinding  ................................ .............................  [ADDRESS_927087] discontinuation/withdrawal  ................................ ..... 31 
7.1 Discontinuation of trial treatment  ................................ ................................ ................................ .. 32 
7.1.1  Temporary discontinuation of trial treatment  ................................ ................................ .. 33 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 3 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927088] discontinuation/withdrawal from the trial  ................................ ................................ .........  [ADDRESS_927089] to follow -up ................................ ................................ ................................ ...........................  33 
8 Trial assessments and procedures  ................................ ................................ ................................ .........  34 
8.1 Efficacy assessments  ................................ ................................ ................................ ......................  35 
8.1.1  Self-measured plasma glucose (SMPG)  ................................ ................................ ..........  35 
8.1.2  Clinical outcome assessments  ................................ ................................ .........................  35 
8.1.3  Clinical efficacy laboratory assessments  ................................ ................................ .........  36 
8.2 Safety assessments  ................................ ................................ ................................ .........................  36 
8.2.1  Insulin dose  ................................ ................................ ................................ ......................  36 
8.2.2  Physical  examinations  ................................ ................................ ................................ ..... 37 
8.2.3  Vital signs  ................................ ................................ ................................ ........................  37 
8.2.4  Electrocardiograms  ................................ ................................ ................................ ..........  37 
8.2.5  Eye examination  ................................ ................................ ................................ ..............  38 
8.2.6  Clinical safety laboratory assessments  ................................ ................................ ............  38 
8.3 Adverse events and serious adverse events  ................................ ................................ ....................  39 
8.3.1  Time period and frequency for collecting AE and SAE information  ..............................  41 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ ................  41 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ...........................  41 
8.3.4  Regulatory reporting requirements for SAEs  ................................ ................................ .. 41 
8.3.5  Pregnancy  ................................ ................................ ................................ ........................  42 
8.3.6  Cardiovascul ar and death events  ................................ ................................ .....................  42 
8.3.7  Technical complaints  ................................ ................................ ................................ ....... 42 
8.4 Treatment of overdose  ................................ ................................ ................................ ...................  42 
8.5 Pharmacokinetics  ................................ ................................ ................................ ...........................  43 
8.6 Pharmaco dynamics  ................................ ................................ ................................ ........................  43 
8.7 Genetics  ................................ ................................ ................................ ................................ .........  43 
8.8 Biomarkers  ................................ ................................ ................................ ................................ ..... 43 
8.9 Immunogenicity  assessments  ................................ ................................ ................................ .........  43 
8.9.1  Hypersensitivity  ................................ ................................ ................................ ...............  43 
8.10  Health economics  ................................ ................................ ................................ ...........................  44 
9 Statistica l considerations  ................................ ................................ ................................ ........................  44 
9.1 Statistical hypotheses  ................................ ................................ ................................ .....................  44 
9.2 Sample size determination  ................................ ................................ ................................ .............  45 
9.3 Populations for analyses  ................................ ................................ ................................ ................  46 
9.4 Statistical analyses  ................................ ................................ ................................ .........................  47 
9.4.1  General considerations  ................................ ................................ ................................ .... 47 
9.4.2 Primary endpoint  ................................ ................................ ................................ .............  47 
9.4.3  Secondary endpoints  ................................ ................................ ................................ ........  48 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ ..... 48 
9.4.4  Exploratory endpoints  ................................ ................................ ................................ ..... 50 
9.4.5  Other safety analyses  ................................ ................................ ................................ ....... 50 
9.4.6  Other analyses  ................................ ................................ ................................ .................  50 
9.5 Interim analyses  ................................ ................................ ................................ .............................  50 
9.6 Data monitoring committee  ................................ ................................ ................................ ...........  50 
9.7 Reporting of the main part of the trial ................................ ................................ ............................  51 
10 Supporting documentation and operational considerations  ................................ ...............................  51 
10.1  Appendix 1: Regulatory, ethical, and trial oversight considerations  ................................ .............  51 
10.1.1  Regulatory and ethical considerations  ................................ ................................ .............  51 
10.1.2  Financial disclosure  ................................ ................................ ................................ .........  51 
10.1.3  Informed consent process  ................................ ................................ ................................  52 
10.1.4 Information to subjects during trial  ................................ ................................ .................  52 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 4 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  5 of 89 
 
   
 10.1.5  Data protection  ................................ ................................ ................................ ................  52 
10.1.6  Committees structure  ................................ ................................ ................................ ....... 53 
[IP_ADDRESS]  Novo Nordisk safety committee ................................ ................................ ...... 53 
[IP_ADDRESS]  Data monitoring committee ................................ ................................ .............  53 
[IP_ADDRESS]  Event adjudication committee  ................................ ................................ .........  53 
10.1.7  Dissemination of clinical trial data  ................................ ................................ ..................  53 
10.1.8  Data quality assurance  ................................ ................................ ................................ ..... 53 
[IP_ADDRESS] Case report forms  ................................ ................................ ............................  53 
[IP_ADDRESS]  Monitoring  ................................ ................................ ................................ ...... 54 
[IP_ADDRESS]  Protocol compliance  ................................ ................................ ........................  55 
10.1.9  Source documents  ................................ ................................ ................................ ............  55 
10.1.10  Retention of clinical trial documentation  ................................ ................................ ........  55 
10.1.11  Trial and site closure  ................................ ................................ ................................ ....... 56 
10.1.12  Responsibilities ................................ ................................ ................................ ................  56 
10.1.13  Indemnity statement  ................................ ................................ ................................ ........  57 
10.1.1 4 Publication policy  ................................ ................................ ................................ ............  57 
[IP_ADDRESS]  Communication of results  ................................ ................................ ...............  57 
[IP_ADDRESS]  Authorship  ................................ ................................ ................................ ....... 58 
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s) ................................ .................  58 
[IP_ADDRESS]  Investigator access to data and review of results  ................................ ............  58 
10.2  Appendix 2: Clinical laboratory tests  ................................ ................................ ............................  59 
10.3  Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, follow -
up, and reporting  ................................ ................................ ................................ ............................  61 
10.3.1  Definition of AE  ................................ ................................ ................................ ..............  61 
10.3.2  Definition of an SAE  ................................ ................................ ................................ ....... 61 
10.3.3  Description of event(s) for adjudication and AEs requiring additi onal data 
collection  ................................ ................................ ................................ .........................  62 
10.3.4  Recording and follow -up of AE and/or SAE  ................................ ................................ ... 64 
10.3.5  Reporting of SAEs  ................................ ................................ ................................ ...........  66 
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  ............................  69 
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow -up and reporting  ................................ ................................ ................................ .................  72 
10.5.1  Definition of technical complaint  ................................ ................................ ....................  72 
10.5.2  Recording and follow -up of technical complaints  ................................ ...........................  72 
10.5.3  Reporting of technical complaints  ................................ ................................ ...................  73 
10.6  Appendix 6: Medical device adverse events, adverse device effects, serious adverse events 
and device deficiencies: Definition and procedures for recording, evaluating, follow -up, and 
reporting  ................................ ................................ ................................ ................................ .........  74 
10.6.1  Definition of AE and adverse device effects (ADE)  ................................ .......................  [ADDRESS_927090] (SADE) and  unanticipated serious 
adverse device effect ([LOCATION_003]DE)  ................................ ................................ ......................  74 
10.6.3  Definition of device deficiency  ................................ ................................ .......................  75 
10.6.4  Recording and follow -up of AE and/or SAE and device deficiencies  ............................  75 
10.6.5  Reporting of SAEs  ................................ ................................ ................................ ...........  78 
10.6.6  Reporting of device deficiencies  ................................ ................................ .....................  78 
10.7  Appendix 7: Retention of human biosamples  ................................ ................................ ................  78 
10.8  Appendix 8: Hypoglycaemic epi[INVESTIGATOR_1841]  ................................ ................................ ...........................  80 
10.9  Appendix 9: Titration guideline  ................................ ................................ ................................ ..... 82 
10.10  Appendix 10: Country -specific requirements  ................................ ................................ ................  84 
10.11  Appendix 11: Abbreviations  ................................ ................................ ................................ ..........  [ADDRESS_927091] of key staff and relevant departments and suppliers  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 5 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927092] of key staff and relevant departments . 
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 6 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  7 of 89 
 
   
 1 Protocol summary  
1.1 Synopsis  
Rationale:  
The present trial is a 52 -week trial designed to investigate the effectiveness and safety of once 
weekly insulin icodec used with DoseGuide in comparison to once daily basal insulin analogues 
both in combination with any non -insulin antidiabetic medication in insulin -naïve subjects with type 
2 diabetes mellitus (T2D) in a clinical practice setting. Thi s trial will provide data on adherence, 
persistence (stay -time on treatment, rate of discontinuation) and patient reported outcomes. In 
addition, the trial will provide long -term exposure data (52 weeks). The long -acting basal insulin 
products currently ap proved for treatment of T2D are administered once or twice daily. The once 
weekly treatment regimen for insulin icodec would become a more convenient basal insulin which 
could improve treatment adherence and overcome insulin initiation barriers as compared  to once 
daily or twice daily basal insulin for subjects with T2D.  
Objectives and endpoints:  
The primary objective of this trial is to demonstrate the effectiveness on glycaemic control of once 
weekly insulin icodec used with DoseGuide in combination with  non-insulin anti -diabetic drugs in 
insulin naïve subjects with T2D in a clinical practice setting. This includes comparing the treatment 
difference in change from baseline in HbA 1c between insulin icodec and once daily basal insulin 
analogues after 52 wee ks of treatment to a non -inferiority limit of 0.3%.  
Endpoint title  Time frame  Unit  
Change in HbA 1c From baseline week 0 (V2) to week 52 (V6)  %-point  
 
The estimand is the ‘treatment policy estimand’ defined as the treatment difference between insulin 
icodec used with DoseGuide and basal insulin analogues of the change in HbA 1c from baseline to 
week 52 for all randomised subjects, irrespective of adherence to randomised treatment and changes 
to antidiabetic background medication. The following intercurr ent events will be handled by [CONTACT_684289]: discontinuation of randomised insulin treatment, and withdrawal from the 
trial (measurements collected after these intercurrent events are used in the primary analysis). This 
estimand aims to ref lect effectiveness of the treatment on a population level in clinical practice.  
Overall design:  
This is a 52 -week, randomised, open label, parallel -group, active -controlled, multi -centre, multi -
national trial with real world elements comparing insulin icodec versus once daily basal insulin 
analogues among insulin naïve T2D subjects in which insulin i nitiation is needed. Subjects 
randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their 
titration.  
The decision that insulin initiation is indicated is at the investigator’s discretion. Potential eligible 
subjects will be identified by [CONTACT_684290]. The 
investigator will have determined the subjects eligible for treatment with basal  insulin including 
insulin icodec prior to informed consent. Which basal insulin the subjects are to initiate, either 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 7 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927093] of care, will be allocated by 1:1 randomisation.  
Key inclusion criteria:  
1. Informed consent obtained before any trial -related activities. Trial -related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.  
2. Male or female.  
3. Age above or equal to 18 years at the time of signing informed consent.  
4. Diagnosed with T2D ≥ 180 days prior to the day of screening.  
5. HbA 1c above 7.0% (53 mmol/mol) as measured by [CONTACT_35970].  
6. Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day 
of screening is allowed, as is prior insulin treatment for gestational diabetes.  
7. Stable daily dose(s) ≥ 90 days prior to the day of screening of any of the following antidiabetic 
drug(s) or c ombination regimen(s):  
a. Any metformin formulations ≥ 1500 mg or maximum tolerated or effective dose.  
b. Any metformin combination formulations ≥ 1500 mg or maximum tolerated or 
effective dose.  
c. Any of the following non -insulin antidiabetic drug classes includin g combinations (≥ 
half of the maximum approved dose according to local label or maximum tolerated 
or effective dose):  
i. Sulfonylureas  
ii. Meglitinides (glinides)  
iii. DPP-4 inhibitors  
iv. SGLT2 inhibitors  
v. Thiazolidinediones  
vi. Alpha -glucosidase inhibitors  
vii. Oral combination p roducts (for the allowed individual Oral Antidiabetic 
Drugs (OADs))  
viii. Oral or injectable GLP -1-receptor agonists  
8. Intensification with insulin is indicated to achieve glycaemic target (4.4 -7.2 mmol/L, 80 -130 
mg/dL) at the discretion of the treating  investigat or. 
Key exclusion criteria:  
1. Known or suspected hypersensitivity to trial product(s) or related products.  
2. Previous participation in this trial. Participation is defined as signed informed consent.  
3. Female who is pregnant, breast -feeding or intends to become pregnant or is of child -bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measures as 
required by [CONTACT_17993]).  
4. Participation in any clinical trial of an approved or non -approved investigational medic inal 
product within 30 days before screening. *  
5. Any disorder which in the investigator’s opi[INVESTIGATOR_36174]’s safety.  
 
*Simultaneous participation in a trial with the primary objective of evaluating an approved or non -
approved investigational medicinal product for prevention or treatment of COVID -19 disease or 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 8 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927094] has 
been received more than 30 days before screening  
Number of subjects:  
Approximately [ADDRESS_927095].  
Treatment groups and duration:  
The trial durat ion is approximately 59 weeks, consisting of a 2 -week screening period, followed by 
a 52-week randomised treatment period and a 5 -week follow -up period. Subjects will be 
randomised 1:[ADDRESS_927096] at the discretion of the 
investigator.  
 
The following trial products will  be supplied by [CONTACT_111393]:  
• Insulin icodec 700 units/mL, s.c., solution for injection, 3 mL PDS290 pre -filled 
pen-injector  
• DoseGuide System  
• Insulin Glargine 100 units/mL, s.c., solution for injection, 3 mL SoloSTAR pre -filled 
pen-injector   
• Insulin Glargine 300 units/mL, s.c., solution for injection, 1.5 mL SoloSTAR pre -filled 
pen-injector  
• Insulin Degludec 100 units/mL, s.c., solution for injection, 3 mL PDS290 pre -filled 
pen-injector  
Data monitoring committee: No 
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 9 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  12 of 89 
 
   
 2 Introduction  
Diabetes mellitus is a metabolic disorder characterised by [CONTACT_41125], insulin action or both. The chronic hyperglycaemia of diabetes mellitus 
is associated with significant long -term complications, particularly damage, dysfunction and failure 
of various tissues – especially the kidney, eye, nerves, heart and blood vessels .1 Diabetes is 
generally classified according to aetiological factors, where type 1 diabetes (T1D) and type 2 
diabetes (T2D) constitute the vast majority of cases. In the latest edition of the International 
Diabetes Federation’s Diabetes Atlas (2019), the estimated worldwide diabetes prevalence was [ADDRESS_927097] increased to 
700 million.2  
Insulin icodec (proposed INN) is a novel long -acting insulin analogue which is developed to safely 
cover the basal insulin requirements for a full week with a single subcutaneous  (s.c.) injection. 
Insulin icodec has a terminal elimination half -life of approximately [ADDRESS_927098] ence (stay -time on 
treatment, rate of discontinuation) and patient reported outcomes. In addition, the trial will provide 
long-term exposure data (52 weeks) for insulin icodec. The long -acting basal insulin products 
currently approved for treatment of T2D are administered once or twice daily. The once weekly 
treatment regimen for insulin icodec would become a more convenient basal insulin which could 
improve treatment adherence and overcome insulin initiation barriers as compared to once daily or 
twice dail y basal insulin for subjects with T2D.  
Overall, the result of the present trial will be important for evaluating the safety and effectiveness of 
insulin icodec in a clinical practice setting and will be part of the clinical development programme 
for the m arketing authorisation approval of insulin icodec.  
2.2 Background  
Diabetes mellitus  
T2D is characterised by [CONTACT_30361], impaired insulin secretion, increased hepatic glucose 
output due to glucagon dysregulation resulting in chronic hyperglycaemia.4 The pathogenesis is not 
fully under stood but seems to be heterogeneous, involving environmental, lifestyle, and genetic 
factors leading to chronic hyperglycaemia caused by [CONTACT_111394], impaired 
insulin secretion due to abnormal beta -cell function and abnormal glucos e metabolism in the liver.5 
The current treatment cascade follows a stepwise approach comprising lifestyle changes in  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 12 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  13 of 89 
 
   
 combination with pharmacological intervention. Metformin is recommended as initial 
pharmacological therapy, followed by [CONTACT_684291] 
(OADs), glucagon -like peptide 1 receptor agonists (GLP -1) and/or insulin as the disease 
progresses.6 On average, after failure of diet and exercise alone, patients require a new intervention 
with glucose -lowering agents every 3 -4 years in order to obtain/retain good glycaemic control.7 
Clinical inertia, often resulting from a resistance to insulin initiation and intensification, is a major 
contributing factor to patients with T2D who are not achieving recommended glycaemic targets.8, 9 
Increased conveni ence is believed to support timely insulin initiation in the treatment for T2D and 
thereby [CONTACT_111396].  
Insulin icodec  
Insulin icodec is a novel long -acting insulin analogue which is developed to safe ly cover the basal 
insulin requirements for a full week with a single subcutaneous (s.c.) injection. Insulin icodec has a 
terminal elimination half -life of approximately 196 hours. The molecule consists of a peptide 
backbone and a fatty acid -containing sid e-chain. The peptide backbone is more resistant towards 
proteolytical degradation compared to human insulin and the side chain gives a strong binding to 
albumin. Both features contribute to the long action of insulin icodec.  
The development programme for insulin icodec is currently ongoing. Three clinical pharmacology 
trials, NN1436 -4314 [T2D], NN1436 -4226 [renal impaired] and NN1436 -4422 [T1D] have been 
completed. No unexpected safety concerns were identified. Two clinical pharmacology trials 
(NN1436 -4462  [T2D]) and NN1436 -4225 [T1D] are currently ongoing.  
Three phase [ADDRESS_927099] recently been completed, NN1436 -4465, NN1436 -
4383 and NN1436 -4466. Once weekly insulin icodec was shown to provide comparable glucose 
lowering effects and similar safety profile to insulin glargine (IGlar) U100 in subjects with T2D. 
Results from these trials were used in the development of the insulin icodec titration guideline 
(Appendix 9 (Section 10.9)).   
A comprehensive review of results from the non -clinical and clinical studies of insulin icodec can 
be found in the current edition of the investigator’s brochure (IB)[ADDRESS_927100] clinical practice an d the insulin icodec titration 
guidance (Appendix 9, Section 10.9). The DoseGuide System is considered an investigational 
software as a medical device (SaMD) in this trial and is documented as compliant with standards 
and regulations for medical devices in t he trial countries.  
A comprehensive overview of the DoseGuide System is available in the current edition of the 
investigator’s brochure for the DoseGuide System and any updates hereof.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 13 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  14 of 89 
 
   
 Once daily basal insulin analogues  
The comparator in this trial is co mmercially available once daily basal insulin analogues: insulin 
glargine U100, U300 and insulin degludec U100, fixed combinations with basal insulin are not 
allowed.  
The investigator will determine the subject eligible for treatment with basal insulin an d select a 
once daily basal insulin analogue for the patient as per standard of care prior to randomisation (V1). 
Subjects will then be randomised to either receive insulin icodec or the once daily basal insulin 
analogue selected.  
For further details on t he once daily basal insulin analogues, please refer to the respective 
Investigator’s Brochure, EMA Summary of Products Characteristics (SmPC), US Prescribing 
Information or locally approved Product Information.  
Trial population  
The trial population will c onsist of insulin naïve subjects with T2D on any non -insulin antidiabetic 
medication. The trial population has been chosen to mimic a relatively broad insulin naïve T2D 
patient group expected to receive the drug once marketed. Subjects should be indicated for 
intensification with insulin to achieve glycaemic target at the investigator’s discretion. Eligible 
subjects will be identified by [CONTACT_684292].  
For more information on the trial population, see Sections  4.2, for more information regarding 
inclusion and exclusion criteria see Sections 5.1 and 5.2, respectively  
2.3 Benefit -risk assessment  
2.3.1 Risk assessment  
Main benefits and risks are described in the below sections.  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of insulin icodec10 and the DoseGuide System11 may be found in the 
respective Investigator’s Brochures and any updates hereof.  
For more information about known and expected benefits and risks for once daily basal insulin 
analogue comparators, refer to the respective Investigator’s Brochure, EMA SmPC or locally 
approved Product Information for the relevant p roduct.  
Identified risks for insulin icodec in this section are described as undesirable clinical outcomes for 
which there is sufficient evidence that they are caused by [CONTACT_684293]. Potential risks in this 
section describe undesirable clinical outcomes  for which there is scientific evidence to suspect the 
possibility of a causal relationship with insulin icodec, but where there is currently insufficient 
evidence to conclude that this association is causal.  
A Trial Risk Assessment  has been carried out in accordance with ISO [ZIP_CODE]:2020 to identify  
potential additional risks associated with the  participation in this trial compared to not participate.12 
The scope of the Trial Risk Assessment  includes all procedures, products and their associated 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 14 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927101] time are outside 
scope of the Trial Risk Assessment . Key risks identified in the detailed T rial Risk Assessment  are 
included below.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 15 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927102] of insulin naive subjects with T2D. For all subjects participating in 
this 52 -week trial, the anticipated benefits include improved glycaemic control. Th e titration 
algorithm (Appendix 9, Section 10.9), which specifies recommended adjustments of basal insulin 
dose at different plasma glucose levels, will be used to ensure that subjects receive optimal 
treatment.  
2.3.3 Overall benefit -risk conclu sion 
Insulin icodec is efficacious at clinically relevant doses.  
No new significant safety information that changes the current benefit -risk profile of insulin icodec 
emerged from the ongoing and completed clinical trials. The safety profile of insulin ic odec remains 
in line with the cumulative experience. The titration algorithm implemented in the DoseGuide 
System is based on the completed clinical trials and is similar in all phase 3a trials. The DoseGuide 
System has been developed to be, and is document ed as, compliant with  applicable  standards and 
regulations for medical devices.11 
As an overall assessment, Novo Nordisk evaluates that the benefit -risk balance of insulin icodec 
used with DoseGuide remains favourable.  
Considering the measures taken to minimise risk to subjects p articipating in this trial, the risks 
identified in association with insulin icodec are justified by [CONTACT_684294].  
3 Objectives and endpoints  
3.1 Primary, secondary and exploratory objective an d estimand  
3.1.1 Primary objective  
To demonstrate the effectiveness on glycaemic control of once weekly insulin icodec used with 
DoseGuide in combination with non -insulin anti -diabetic drugs in insulin naïve subjects with T2D 
in a clinical practice setting. This  includes comparing the difference in change from baseline in 
HbA 1c between insulin icodec used with DoseGuide and once daily basal insulin analogues after 52 
weeks of treatment to a non -inferiority limit of 0.3%.  
3.1.[ADDRESS_927103] on s afety and patient reported outcomes related to treatment satisfaction and 
compliance of once weekly insulin icodec used with DoseGuide versus once daily basal insulin 
analogues both in combination with any non -insulin antidiabetic drugs in insulin -naïve su bjects 
with T2D in a clinical practice setting.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 18 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  19 of 89 
 
   
 Estimand:  
The estimand is the ‘treatment policy estimand’ defined as the treatment difference between insulin 
icodec used with DoseGuide and basal insulin analogues of the change in HbA 1c from baseline to 
week 52 for all randomised subjects, irrespective of adherence to randomised treatment and changes 
to antidiabetic background medication. The following intercurrent events will be handled by [CONTACT_684289]: discontinuation of investigational me dical products, and withdrawal from 
the trial (measurements collected after these intercurrent events are used in the primary analysis). 
This estimand aims to reflect effectiveness of the treatment on a population level in clinical 
practice.  
3.2 Primary, seco ndary and exploratory endpoints  
3.2.1 Primary endpoint  
Endpoint title  Time frame  Unit  
Change in HbA 1c From baseline week 0 (V2) to week 52 
(V6)  %-point  
 
3.2.2 Secondary endpoints  
[IP_ADDRESS]  Supportive secondary endpoints  
Supportive secondary effectiveness endpoints   
Endpoint title Time frame  Unit  
Time from baseline to treatment 
discontinuation or intensification  From baseline week 0 (V2) to week 52 
(V6)  Days  
Change in DTSQs (Diabetes Treatment 
Satisfaction Questionnaire) in total 
treatment satisfaction  From baseline week 0 (V2) to week 52 
(V6)  Score of 0 -36.  
6 items scored on a scale of 0 
to 6. The higher the score the 
greater the satisfaction with 
treatment.  
Trim -D (Treatment Related Impact 
Measure for Diabetes) compliance 
domain  At end of treatment week 52 (V6)  Score of  4-20. 
4 items scored on a scale of 1 
to 5 Transformed to a 0 -100 
scale with higher scores 
corresponding to better 
compliance.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 19 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  20 of 89 
 
   
 Supportive secondary safety endpoints  
Endpoint title  Time frame  Unit  
Number of severe hypoglycaemic  
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 57 
(V8)  Number of e pi[INVESTIGATOR_111345] (level 2) (<3.0 
mmol/L (54 mg/dL), confirmed by [CONTACT_339692])  From baseline week 0 (V2) to week 57 
(V8)  Number of e pi[INVESTIGATOR_111345] (level 2) (<3.0 
mmol/L (54 mg/dL), confirmed by [CONTACT_339692]) or severe hypoglycaemic epi[INVESTIGATOR_1841] 
(level 3)  From baseline week 0 (V2) to week 57 
(V8)  Number of e pi[INVESTIGATOR_1841]  
  
3.2.3 Exploratory endpoints  
Endpoint title  Time frame  Unit  
Number of severe hypoglycaemic  
epi[INVESTIGATOR_1841] (level 3)  From baseline week 0 (V2) to week 52 
(V6)  Number of e pi[INVESTIGATOR_1865] s 
Number of clinically significant 
hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 
mmol/L (54 mg/dL), confirmed by [CONTACT_339692])  From baseline week 0 (V2) to week 52 
(V6)  Number of e pi[INVESTIGATOR_1865] s 
Number of clinically significant 
hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 
mmol/L (54 mg/dL), confirmed by [CONTACT_339692]) or severe hypoglycaemic epi[INVESTIGATOR_1841] 
(level 3)  From baseline week 0 (V2) to week 52  
(V6)  Number of e pi[INVESTIGATOR_1865] s 
 
[ADDRESS_927104] s in which insulin initiation is 
needed.  
The trial duration is approximately 59 weeks, consisting of a 2 -week screening period, followed by 
a 52-week randomised treatment period and a 5 -week follow -up period . The overall trial design and 
visit schedule ar e outlined in Figure  4-1 and trial flowchart (see Section  1.2), respectively.  
 
 
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 20 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927105]'s practicing physician who in clinical practice would be initiating the subject on insulin.  
The decision that insulin initiation is indicated is at the investigator’s discretion. Potential eligible 
subjects will be identified by [CONTACT_684295]. The investigator will 
have determined the subjects eligible for treatment with basal insulin including insulin icodec prior 
to informed consent; however, the allocation to initiate insulin icodec o r once daily basal insulin 
analogue will be made by [CONTACT_17975]. Subjects will be randomised 1:[ADDRESS_927106] of care. No str atification will be conducted.  
Diagnostic and monitoring procedures outside of normal clinical practice are employed to ensure 
sufficient AE collection to comply with phase 3a requirements and further described below. The 
trial will include: Informed conse nt, randomisation and treatment initiation visit (dedicated 
randomisation visit), a dedicated trial visit at 13, [ADDRESS_927107] at the discretion of the 
investigator. AE collection will continue with 2 follow -up contacts (V7 and V8). The follow -up 
period is 5 weeks. Due to different dosing intervals  (weekly vs daily) and the longer half -life of 
insulin icodec, the last follow -up visit (V8) is scheduled to take place [ADDRESS_927108] dose of once daily basal insulin analogue.  
Additio nal visits are allowed throughout the trial. It is anticipated that investigators, as the subjects' 
physicians, ensure subjects undergo medical evaluation at regular intervals over the course of the 
trial as per standard of care. Subjects will be encourage d to reach out proactively if experiencing 
any alterations to their wellbeing which may represent an AE. AEs will be assessed at all contacts 
and subjects will have an eDiary to report hypoglycaemic epi[INVESTIGATOR_1841] (Appendix  8, Section 10.8).  
To allow treatment according to local practice all non -insulin antidiabetic medications as standard 
of care are allowed at the investigator’s discretion during the trial . Add -on, discontinuation or dose 
modification of non -insulin antidiabetic medications is allowed at any time during the trial.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 21 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927109] should attend a n early  
discontinuation follow -up visit (V6A)  and continue marketed antidiabetic medications including 
insulins at the discretion of the investigator for the remainder of the trial.  
Event adjudicatio n will be performed for acute coronary syndrome events (acute myocardial 
infarction and unstable angina pectoris requiring hospi[INVESTIGATOR_11956]), cerebrovascular events (stroke 
and transient ischemic attack), heart failure (requiring hospi[INVESTIGATOR_684278] h eart failure visit) 
and all cause death.  
4.[ADDRESS_927110] allowing for local clinical 
practice to be maintained. Investigators, as the subjects’ physicians, are expected to schedule 
additional visits as they deem relevant. It is therefore expected that the investigator together with 
the patient agrees to a tailored visit schedule during the conduct of the trial  in addition to the 
planned visits according to the flow chart . 
The treatment duration of 52 weeks is evaluated to be adequate time for assessing effectiveness on 
glycaemic control and safety. This duration will also allow for up -titrating of the basal insulin.  
A centralized treat -to-target approach will not be applie d as titration of basal insulin analogues 
should be done according to local labelling and clinical practice. Use of a marketed titration support 
mobile app or tool to aid titration of the once daily basal insulin analogue comparators is allowed at 
the disc retion of the investigator.  
Titration of insulin icodec should be conducted in accordance with the titration guideline, see 
Appendix 9 (Section 10.9). Titration of insulin icodec will be aided by [CONTACT_684296], which calculates the dose recommendations with the same titration algorithm as outlined in 
the titration guideline and will provide insulin icodec dose recommendations via the Dose Guide app 
to subjects. (see the current DoseGuide System IB for more information).  
During the treatment period, the subjects will have dedicated site visits every three months, in 
accordance with recommended clinical practice, with the option of additional  site visits or phone 
contacts according to local clinical practice or need. The last follow -up visit is planned to be [ADDRESS_927111] 5 half -lives of i nsulin icodec.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 22 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  23 of 89 
 
   
 Subjects included in the trial can be on any non -insulin antidiabetic medication, however to 
minimise the risk of hypoglycaemia subjects treated with glinides or sulfonylureas (either alone or 
in combination with other OADs) will be asked to reduce the dos e by [CONTACT_3450] 50% at the 
discretion of the investigator. Underlying diseases such as recent cardiac problems, impaired liver 
or renal function will be documented prior to treatment initiation but are not exclusion criteria. 
However, any condition cons idered to jeopardise subject’s safety as assessed by [CONTACT_684297]. As no human data are available on pregnancies 
following exposure to insulin icodec, female subjects of childbearing potential can only be recruited 
if adequate contraceptive methods are used (see Appendix 4, Section 10.4).  
Overall, the eligibility criteria will allow for enrolment of a relatively broad insulin naïve T2D 
population resembling one of the key target populations for insulin icodec use.  
4.[ADDRESS_927112] to one unit of insulin glargine 100 
units/mL and one unit of insulin degludec 100 units/mL, and therefore once weekly dosing 
corresponds to seven times th e daily dose of a once daily basal insulin  comparator . Basal insulin 
analogue comparators should be initiated as per the discretion of the investigator based on local 
clinical practice.   
The PK/PD properties of insulin icodec following five weeks of once weekly dosing in subjects 
with T2D (trial NN1436 -4314) showed that insulin icodec exposure was well distributed across the 
dosing interval, with a PK profile suitable for once weekly dosing. Insulin icodec was well tolerated 
in subjects with T2D and no une xpected safety concerns were identified after multiple once weekly 
dosing in the dose range of 12−24 nmol/kg (2 -4 units/Kg).  
After randomisation, subjects will initiate insulin injections and this treatment should continue until 
52 weeks after randomisatio n where the subjects come in for the end of treatment visit (V6).  
Initiation and titration of daily basal insulin analogues will be done according to approved label and 
local clinical practice. Initiation and titration of insulin icodec should be conducte d in accordance 
with the titration guideline aided by [CONTACT_684298], see Appendix 9 (Section 10.9).  
4.[ADDRESS_927113] completed the trial if he/she has completed all phases of the trial 
including the last visit.  
The end of the trial is defined as the date of the last visit of the last subject in the trial globally . 
5 Trial population  
Prospective appro val of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 23 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  24 of 89 
 
   
 5.1 Inclusion criteria  
Subjects are eligible to be included in the trial only if all the following criteria apply:  
1. Informed consen t obtained before any trial -related activities. Trial -related activities are any  
procedures that are carried out as part of the trial, including activities to determine suitability for  
the trial.  
2. Male or female.  
3. Age above or equal to 18 years at the time o f signing informed consent.  
4. Diagnosed with T2D ≥ 180 days prior to the day of screening.  
5. HbA 1c above 7.0% (53 mmol/mol) as measured by [CONTACT_35970].  
6. Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to the day 
of screening is allowed, as is prior insulin treatment for gestational diabetes.  
7. Stable daily dose(s) ≥ 90 days prior to the day of screening of any of the following antidiabetic 
drug(s) or combination regimen(s):  
a. Any metformin formulations ≥  1500 mg or maximum tolerated or effective dose.  
b. Any metformin combination formulations ≥ 1500 mg or maximum tolerated or 
effective dose.  
c. Antidiabetic Drugs including combination products (≥ half of the maximum 
approved dose according to local label or max imum tolerated or effective dose):  
• Sulfonylureas  
• Meglitinides (glinides)  
• DPP-4 inhibitors  
• SGLT2 inhibitors  
• Thiazolidinediones  
• Alpha -glucosidase inhibitors  
• Oral combination products (for the allowed individual Oral Antidiabetic 
Drugs (OADs))  
• Oral or injecta ble GLP -1-receptor agonists  
8. Intensification with insulin is indicated to achieve glycaemic target (4.4 -7.2 mmol/L; 
80-130 mg/dL) at the discretion of the treating  investigator . 
5.2 Exclusion criteria  
Subjects are excluded from the trial if any of the following  criteria apply:  
1. Known or suspected hypersensitivity to trial product(s) or related products.  
2. Previous participation in this trial. Participation is defined as signed informed consent.  
3. Female who is pregnant, breast -feeding or intends to become pregnant or  is of child -bearing 
potential and not using an adequate contraceptive method (adequate contraceptive measures as 
required by [CONTACT_17993]).  
4. Participation in any clinical trial of an approved or non -approved investigational medicinal 
produc t within 30 days before screening. * 
5. Any disorder which in the investigator’s opi[INVESTIGATOR_36174]’s safety.  
 
*Simultaneous participation in a trial with the primary objective of evaluating an approved or non -
approved investigational medicinal product for prevention or treatment of COVID -19 disease or 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 24 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927114] once cigarette or equivalent daily.  
5.4 Screen failures  
Screen failures are defined as subjects who consent to participate in the clinical trial but are not 
eligible for participation according to inclusion/exclusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporti ng of screen failure subjects to meet 
requirements from regulatory authorities. Minimal information includes informed consent date,  
demography, screen failure details and eligibility criteria.  
A screen failure session must be made in the interactive web re sponse system (IWRS).  
Individuals who do not meet the criteria for participation in this trial may not be rescreened. If the 
subject has failed one of the inclusion criteria or fulfilled one of the exclusion criteria related to 
laboratory parameters, re -sampling is not allowed. However, in case of technical issues (e.g. 
haemolysed or lost), re -sampling is allowed for the affected parameters.  
5.5 Run-in criteria, randomisation criteria and dosing day criteria  
This section is not applicable for this trial.  
6 Treatm ents 
6.1 Treatments administered  
Treatments include the investigational medicinal products ( Section 6.1) and investigational medical 
device ( Section [IP_ADDRESS] ) provided by [CONTACT_3454].  
Inves tigational medicinal products (IMP)  
All investigational medical products (IMPs) provided by [CONTACT_684299]  6-1. 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 25 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927115] 
name:  [CONTACT_111445]  
700U/mL  
(IMP, test product)  Insulin Degludec  
100U/mL  
(IMP, reference 
therapy)  Insulin Glargine  
100U/mL  
(IMP, reference 
therapy)  Insulin Glargine  
300U/mL  
(IMP, reference 
therapy)  
Dosage form  Solution for injection  Solution for injection  Solution for injection  Solution for injection  
Route of 
administration  Subcutaneous (into 
the thigh, upper arm 
or abdomen)  Subcutaneous (into the 
thigh, upper arm or 
abdomen)  Subcutaneous (into the 
thigh, upper arm or 
abdomen)  Subcutaneous (into the 
thigh, upper arm or 
abdomen)  
Recommended 
initial dose  Please refer to 
Appendix 9  Please refer to 
Appendix 9  Please refer to 
Appendix 9  Please refer to 
Appendix 9  
Dosing 
instructions  Administer insulin 
icodec once weekly, 
on the same day each 
week, at any time of 
the day.  The day of 
weekly 
administration can be 
changed if necessary, 
by [CONTACT_8622] 3 days. A 
minimum of 4 days 
between injections 
should always be 
ensured.  Administer insulin 
degludec once daily at 
any time of the day, but 
at the same time every 
day throughout the trial. 
Rotation of in jection 
site is recommended.  Administer insulin 
glargine once daily, at 
any time of the day but 
at the same time every 
day throughout the trial. 
Rotation of injection 
site is recommended.  Administer insulin 
glargine once daily, at 
any time of the day but 
at the same time every 
day throughout the trial. 
Rotation of injection 
site is recommended.  
Packaging   3 mL PDS290 pre -
filled pen -injector   3 mL PDS290 pre -filled 
pen-injector  3 mL SoloSTAR pre -
filled pen -injector  1.5 mL SoloSTAR 
pre-filled pen -injector  
• Subjects should administer insulin icodec at site at the randomisation visit (V2).  
• Subjects should initiate basal insulin analogues as per clinic’s standard of care.   
• Subjects should be instructed to discard the needle after each injection and store the pen -
injector without a needle attached.  
• Subjects should be  instructed to use one pen injector for the full in -use time period ( see 
TMM) . The subjects should change the pen-injector only if the inuse time is passed or a full 
dose can no longer be given . 
Non-investigational medicinal products (NIMP)  
After randomisation subjects can continue add -on or remove non -insulin anti -diabetic medication in 
agreement with the investi gator and according to local clinical practice throughout the entire trial; 
however, subjects with glinides or sulfonylureas (either alone or in combination with other OADs) 
will be asked to reduce the dose by [CONTACT_3450] 50% at the discretion of the inv estigator, at 
randomisation. There is no requirement that background medication should be stable or maintained 
at the pre -trial dose and dose adjustments are allowed during the entire treatment period. Please see 
section 6.5 for reporting of concomitant anti -diabetic medications.  
In addition, the background medication:  
• is considered to be non -investigational medicinal product (NIMP)  
• will not be provided by [CONTACT_684300].  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 26 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927116] document th at training in the DFU for the DoseGuide App has been given to 
the subjects orally and in writing at randomisation (V2) and should be repeated during the trial to 
ensure correct use of the medical device.  
[IP_ADDRESS]  Non-investigational medical device  
Needles for pre -filled pen -injectors are listed in Table  6-2. 
Blood Glucose Meter (BG Meter)  
For self -measuring of blood glucose during the trial, subjects will be provided with a BG meter at 
randomisation (V2) including auxiliaries and instructions for  use.  
At randomisation (V2) the subjects must be instructed in how to use the BG meter . For subjects 
randomised to basal insulin analogues, t he BG meter should be paired to the eDiary as described in 
the site guide. For subjects randomised to insulin icod ec, the BG meter should be paired with the 
DoseGuide App as described in the  DoseGuide Portal . 
For further information on the BG Meter, please refer to the manufacturer’s manual.  
6.2 Preparation/handling/storage/accountability  
Only subjects randomised to treatment may use trial product and only delegated site staff may 
supply trial product. Trial product includes both the investigational medical product and the 
investigation al medical device.  
Investigational medicinal products  
• Acceptable temperature ranges  and conditions for storage and handling of trial products 
when not in use and when in use are described in the Trial Material Manual (TMM) and trial 
product label.  
• Each site will be supplied with sufficient trial products for the trial on an ongoing basis . 
Trial product will be distributed to the sites according to screening and randomisation.  
• The investigator or designee must confirm that appropriate temperature conditions have 
been maintained during transit for all trial products received, and that any discrepancies are 
reported and resolved before use of the trial products.  
• All trial products must be stored in a secure, controlled, and monitored (manual or 
automated) area in accordance with the labelled storage conditions with access limited to the 
investigator and delegated site staff.  
• The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditions. The trial product must not be dispensed to any subject before it 
has been evaluated and approved for  further use by [CONTACT_3454]. Additional details 
regarding handling of temperature deviations can be found in the TMM.  
• The investigator or designee is responsible for drug accountability and record maintenance 
(i.e. receipt, accountability and final dispos ition records).  
• The investigator or designee must instruct the subject in what to return at next visit . 
• Drug accountability should be performed at pen level  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 28 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  29 of 89 
 
   
 • Destruction of trial products can be performed on an ongoing basis and will be done 
according to l ocal procedures after accountability is finalised by [CONTACT_17996].  
• All returned, un -used,  expi[INVESTIGATOR_17945] (for technical complaint samples, 
see Section 10.5) must be stored separately from non -allocated trial products. No 
temperature monitoring is required.  
• Non-allocated trial products including expi[INVESTIGATOR_41073], at the  latest at closure of the site.  
Investigational medical device  
• The investigational medical device described in Section [IP_ADDRESS]  will be supplied by 
[CONTACT_684301].  
• The investigator or designee is responsible for DoseGuide App device accountability via 
subje ct access control through DoseGuide portal.  
• Device accountability should be performed at subject account level .  
• The provisioned study phone is not considered a medical device, but a carrier of the apps to 
be used in the trial.  
• The provisioned study phones  must be returned by [CONTACT_684302].  
• All returned, unused or damaged study phones must be stored separately and returned at the 
latest at closure of the site.  
• Investigator a ccountability is not applicable for the DoseGuide Portal and  the DoseGuide 
Cloud. Instead, Novo  Nordisk will control and restrict access to these systems.  
6.3 Measures to minimise bias: Randomisation and blinding  
This is an open -label trial; however, the specific treatment for a subject will be assigned using an 
IWRS. The site will access the IWRS before the start of trial product administration for each 
subject. Potential bias will be reduced by [CONTACT_684303]. All subjects will be centrally screened and randomised usi ng an IWRS and assigned to the 
next available treatment according to randomisation schedule. Trial product will be 
dispensed/allocated at the trial visits summarised in the flowchart.  
6.[ADDRESS_927117]’s compliance as per standard clinical 
practice.  
When subjects self -administer IMP at home, compliance with trial product administration should be 
assessed by [CONTACT_684304] t he expected use:  
• Drug accountability information; counting returned trial product, visual inspection of pens  
• Review of DoseGuide App, SMPG profiles, insulin dose and hypoglycaemia reporting via 
HCP web portals.  
• Evaluating glycaemic control and adherence  to the visit schedule  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 29 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  30 of 89 
 
   
 • If any suspi[INVESTIGATOR_17946] -compliance arises the site should enter into a dialogue with the 
patient as per standard clinical practice. This dialogue must be documented in the medical 
record.  
DoseGuide App Compliance  
The DoseGuide App i s only applicable for subjects randomised to insulin icodec. Subjects should 
initiate insulin icodec with DoseGuide to aid titration.  
Permanent s uspension of the DoseGuide App will result in discontinuation of insulin icodec 
treatment.   
6.[ADDRESS_927118] is receiving from the screening visit (V1) until end of trial (V8) visit must be recorded along 
with:  
• Generic name [CONTACT_111446]   
• Indication   
• Dates  of administration including start and stop dates  
Concomitant medication (diabetes)  
Any anti -diabetic medication that the subject receives from screening (V1) to end of trial (V8) must 
be recorded in a separate concomitant medication (diabetes) form in the  eCRF. This does not 
include the IMP (insulin icodec or basal insulin analogue) that the subject was randomised to at V2.  
The following information must be recorded for oral antidiabetic drugs (OADs), GLP -[ADDRESS_927119] -treatmen t insulin in the follow -up period:  
• Trade name [CONTACT_684325]  
• Doses and frequency (e.g. once daily, twice daily)  
• Dates of administration including start and stop dates  
If the investigator chooses to initiate anti -diabetic medication or change dose of pre -trial anti -
diabetic background medication prior to end of treatment, this should be registered in the eCRF as 
change in concomitant medication (diabetes). If subject req uires intensification of basal insulin or 
continuous use of bolus insulin, please see Section 7. 
Changes in concomitant medication including antidiabe tic and other indications must be recorded at 
each visit. If a change is due to an AE, then this must be reported according to Section 8.3. 
For information regarding concomitant medication collection including antidiabetic and other 
indications for subjects who discontinue trial product see Section 7.  
6.5.1 Rescue medication or Rescue therapy  
This section is not applicable for this trial   
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 30 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  31 of 89 
 
   
 6.6 Dose modification  
Insulin icodec doses are adjusted according to the titration guidelines ba sed on SMPG values as 
described in Appendix 9 (Section  10.9). 
The recommended insulin icodec doses are provided directly to subjects randomised to insulin 
icodec via the DoseGuide App. The subject receives dose recommendations through the DoseGuide 
App within the scope of a pre -planned treatment program from the investigator.  
The titration algorithm may not be applicable in certain clinical situations and the recommended 
doses can therefore be overruled. The investigator can view and change the dose rec ommendation 
based on the data collected via the DoseGuide Portal at his/her discretion. The investigator can also 
suspend or re -initiate use of the DoseGuide App at his/her discretion. Permanent discontinuation of 
the DoseGuide App will lead to discontinua tion of insulin icodec treatment (see Section 6.4 and 7).   
For more information on the DoseGuide System, please refer to the IB and any updates thereof.  
Titration of once daily basal insulin analogue comparators is at the discretion of the invest igator as 
per the clinic’s standard of care. The recommended doses for all once daily basal insulin analogues 
will be based on local label. Use of titration assistant applications or other tools is at the discretion 
of the investigator.  
Please see the Ins ulin Titration Guideline (Appendix 9, Section 10.9) for more information.  
6.[ADDRESS_927120] -trial 
treatment includes a new insulin treatment, please refer to the titration guideline 
Appendix  9 (Section 10.9).  
[ADDRESS_927121] 
discontinuation/withdrawal  
Treatment of a subject may be discontinued at any time duri ng the trial at the discretion of the 
investigator . 
Efforts must be made to have the subjects who discontinue IMP attend the end of treatment visit  
(V6) as soon as possible to collect the required data for the analysis of the primary endpoint. Two 
follow -up visits, V7 and V8, must be performed after discontinuation of the IMP. V7 and V8 must 
be conducted [ADDRESS_927122] and report AEs as described in Section 8.3.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 31 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  32 of 89 
 
   
 Only antidiabetic medication should be collected and recorded in the eCRF until V6A for 
discontinued subjects, no other concomitant medication will be collected. Please, refer to 
Section   6.7 for treatment after end of trial.  
Subjects who prematurely discontinue IMP should keep the study phone (containing the eDiary and 
DoseGuide App) and return it at V8.  
Subjects who prematurely d iscontinue insulin icodec should terminate use of the DoseGuide App 
but continue to use the eDiary. Permanent discontinuation of DoseGuide App will result in 
discontinuation of insulin icodec.  
In case of any uncertainty regarding the scheduling of the visi ts after discontinuation or questions to 
said visits, the investigator should consult Novo Nordisk for further guidance.  
Only subjects who withdraw consent will be considered as withdrawn from the trial. Subjects must 
be educated about the continued scient ific importance of their data, even if they discontinue IMP. 
Further, the site should stay in contact [CONTACT_684305]/or site visits to 
motivate subjects to attend the discontinuation visits until the discontinuation follow -up visit  
(V6A). Site contact [CONTACT_111409].  
7.[ADDRESS_927123]:  
1. Safety concern related to trial product  or unacceptable intolerability   
2. Pregnancy  
3. Intention of becoming pregnant  
4. Patients should be advised not to participate in other clinical trials while participating in this 
trial. If done, treatment with trial product should be disctoninued.*  
5. Switch to another basal insulin analogue  
6. Intensification to a basal bolus regime or continuous use of bolus insulin  
*Simultaneous participation in a trial with the primary objective of evaluating an approved or non -
approved investigational medicinal prod uct for prevention or treatment of COVID -19 disease or 
postinfectious conditions is allowed at the investigator’s discretion without discontinuing trial 
product  
The primary reason for discontinuation of IMP must be specified in the end -of-treatment -form  in 
the eCRF, and  final drug accountability must be performed . A treatment status session must be 
made in the IWRS.  
If temporary or permanent discontinuation of DoseGuide App is related to a technical complaint or 
for safety reasons please see Appendix 5, Se ction 10.5.  
A subject who does not fulfil the eligibility (inclusion/exclusion) criteria must not be randomised. 
Randomisation in violation of any of the eligibility criteria is Good Clinical Practice (GCP) 
non-compliance and must be reported to the sponsor without delay. This will be handled as an 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 32 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  33 of 89 
 
   
 important protocol deviation, and the independent ethics committee/institutional review board 
(IEC/IRB)  and regulatory authorities must be notified according to local requirements.  
Subjects that are randomised in violation of inclusion and exclusion criteria can be allowed to 
continue in the trial and receive trial product if there are no safety concerns a s evaluated by [CONTACT_684306].  
7.1.[ADDRESS_927124]  (IMP & DoseGuide System)  are allowed to restart trial 
product, unless any of the discontinuation criteria specified in section 7.[ADDRESS_927125] discontinuation/withdrawal from the trial  
A subject may withdraw consent at any time  at his/her own request. If a subject withdraws consent, 
the investigator must ask the subject if he/she is willing, as soon as possible, to have assessment 
performed according to  end of treatment visit (V6). See flowchart ( 1.2) for data to be collected.  
Final accountability must be performed even if the subject is not able to come to the site . A 
treatment discontinuation session must be made in the IWRS.  
If the subject withdraws consent, Novo Nordisk may retain and continue to use any data collected 
before such a withdrawal of consent.  
If a subject withdraws from the trial, he/she may request destruction of any samples taken and not 
tested, and the i nvestigator must document this in the medical record.  
Although a subject is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where  
the reasons are obtained, the primary reason for withdrawal must be specified in the end of trial 
form  in the eCRF.  
7.2.[ADDRESS_927126]'s source 
document. Should the subject continue to be unreachable at end of trial (V8), he/she will be 
considered to have withdrawn from the trial with a primary reason of `lost t o follow -up'. 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 33 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  34 of 89 
 
   
 8 Trial assessments and procedures  
The following sections describe the assessments and procedures, while their timing is summarised 
in the flowchart.  
• Informed consent must be obtained before any trial related activity, see Section 10.1.3 . 
• All screening evaluations must be completed and reviewed to confirm that potential subjects 
meet all inclusion criteria and none of the exclusion criteria.  
• The investigator will maintain a screening log (e.g. electronic or paper) to record details of 
all subjects screened and to confirm eligibility or record reason for screen failure, as 
applicable.  
• At screening, subjects will be provided with a card stating that they are participating in a 
trial and giving contact [CONTACT_684307].   
• At screening, after confirming eligibility, the investigator will select the once daily basal 
insulin analogue suitable fo r the subject. At V2, the subject will be randomised to either 
insulin icodec or the once daily basal insulin analogue selected at screening.  
• Adherence to the trial design requirements, including those specified in the flowchart, is 
essential for trial co nduct however assessments should be carried out according to the 
clinic’s standard of practice unless specified in the current section. Efforts should be made 
to limit the bias between the assessments.  
• The suggested order of assessments related to the eDi ary, BG meter and DoseGuide System 
at randomisation visit (V2) is as follows:  
o The investigator should create a subject profile and record administrative 
information (e.g. subject ID, year of birth and gender and treatment arm) in the 
eDiary HCP web portal,  and if the subject is randomised to insulin icodec also in the 
DoseGuide Portal  
o Subjects should be provided with a study phone and instructed in how to use the 
eDiary and the DoseGuide App if randomised to insulin icodec  
o The BG meter should be paired wit h the DoseGuide App (for subjects randomised 
to insulin icodec) or to the eDiary (for subjects randomised to basal insulin 
analogues).  
o SMPG should be measured using the BG meter (and transferred to the eDiary or 
DoseGuide App)  
o Dosing of trial product (and entry of dose in eDiary or DoseGuide App)  
• For information regarding the eDiary and eDiary web portal use please refer to the site 
guide.  
• For information regarding the DoseGuide System please refer to the IB or the DFUs . 
• Please refer to Section 6.4 for treatment compliance.  
• For data entered in the eDiary and DoseGuide System via the study phone, eDiary and 
DoseGuide databases are considered source data. The investigator should review all the data 
for the subjects through the eDiary web portal and the DoseGuide Portal, before or during 
each visit/phone contact [CONTACT_684308].  
• Source data of clinical assessments performed and recorded in the eCRF must be available 
and will usually be in the subject’s medical records. Additional recording to be considered 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 34 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  35 of 89 
 
   
 source data include, but is not limited to laboratory reports, BGM, pi[INVESTIGATOR_111353].  
• Review of data on HCP web portal, ECG, laboratory reports, eye - and physical 
examinations must be documented either on the documents or in the subject's source 
documents. If clarification of entries or discrepancies in the eDiary, or DoseGuide App is 
neede d, the subject must be questioned, and a conclusion made in the subject's source 
documents, the eDiary can be updated retrospectively if applicable. Care must be taken not 
to bias the subject. The investigator should ensure that the ePRO questionnaires are  
completed by [CONTACT_111412].  
• Repeat samples may be taken for technical issues and unscheduled samples or assessments 
may be taken for safety reasons. Please refer to Appendix 2 (Section 10.2) for further details 
on laboratory samples . 
8.1 Efficacy assessments   
Planned time points for all efficacy assessments are provided in the flowchart.  
8.1.1 Self-measured plasma glucose (SMPG)  
Subjects will be provided with a BG meter including auxiliaries. The BG meters use test strips 
calibrated to plasma values. Therefore, all measurements performed with capi[INVESTIGATOR_111354], which w ill be shown on the display .  
The BG meter provided by [CONTACT_684309], as described in the flow chart 1.2. 
A baseline SMPG value, should be collected using the BG meter at V2.  
Pre-breakfast daily SMPG  
Subjects should be instructed to measure their pre -breakfast SMPG daily from the day after  
randomisation ( V2) to end of treatment (V6)  and to transfer the SMPG values into the DoseGuide 
App (for subjects randomised to insulin icodec) or the eDiary (for subjects randomised to basal 
insulin analogues ). Subjects should specify pre -breakfast SMPG in the corresponding App. Pre-
breakfast SMPG should be measured daily from end of treatment (V6) to end of trial (V8) and 
captured in the eDiary for all subjects.   
Selected titration data (e.g. certain SMPGs and dose data) will be used during the trial for central 
titration surveillance, to ensure co mpliance with DoseGuide supported titration and will not be 
reported in the clinical trial report. All data will be stored by [CONTACT_3454] (see Appendix 1, 
Section 10.[ADDRESS_927127] without assistance of the site personnel. 
The questionnaires should be completed on site before any other visit related procedures are 
conducted. The three questionnaires take approximately five min utes to complete.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 35 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  36 of 89 
 
   
 The following PRO questionnaires will be supplied in the eDiary in a linguistically validated 
version in all languages relevant for this trial:  
• Diabetes Treatment Satisfaction Questionnaire (DTSQ)  
o The questionnaire has been designed to  measure satisfaction with diabetes treatment 
regimens in people with diabetes. The DTSQ questionnaire will be measured at 
baseline (V2), during conduct (V4) and end of treatment (V6).  
• Treatment Related Impact Measure for Diabetes (TRIM -D) Compliance doma in  
o The TRIM -D questionnaire was developed to capture the impact of diabetes 
treatment on patients’ functioning and well -being. The compliance domain from the 
questionnaire will be used to measure the compliance between the treatment groups. 
The compliance  domain of TRIM -D will be measured end of treatment  (V6).  
• Diabetes Pen Experience Version 3.0 (DPEM)  
o The questionnaire is designed to measure patients experience of insulin injection 
pen in terms of easiness, convenience and satisfaction. The DPEM questio nnaire 
will be measured at end of treatment (V6).  
8.1.3 Clinical efficacy laboratory assessments  
All protocol -required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the flowchart and the laboratory manual . 
8.2 Safety assessments   
Safety assessments should be carried out as per clinic’s standard of care if not otherwise specified 
and in accordance with the flowchart ( 1.2).   
A concomitant illness  is any illness that is already present at the time point from which AEs are 
collected or found as a result of a screening procedure or other trial procedures performed before 
exposure to trial product.   
Medical history is a medical event that the subject experienced  prior to the time point from which 
AEs are collected.  Only relevant medical history as judged by [CONTACT_364065].  
In case of an abnormal and clinically significant finding fulfilling the definition of a concomitan t 
illness or medical history, the investigator must record the finding on the Medical History/ 
Concomitant Illness form.  
8.2.1 Insulin dose  
During the trial, starting at randomisation (V2), subjects must be instructed to report date and dose 
of once weekly insulin icodec in the DoseGuide App and date, dose and time of once daily insulin 
injections in the eDiary. In the follow -up period if the subject switches to a new basal insulin, the 
subject should report date, dose and time of the new basal insulin in the e Diary.  
While using the HCP web portal for titration of once  daily basal insulin analogues, the daily insulin 
prescribed at this contact [CONTACT_684310] . 
The investigator must record the following in the eCRF for all subjects  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 36 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  37 of 89 
 
   
 • First and last date on trial product  
• First and last dose o f trial product  
For information about recommended insulin doses please see Appendix 9, Section 10.9 
8.2.2 Physical examinations  
A physical examination will include assessments of: head, ears, eyes, nose, throat, neck, 
cardiovascular system, respi[INVESTIGATOR_2133], gastrointestinal system, central and peripheral nervous 
system, musculoskeletal system and skin.  
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
The physical examination will be recorded in the eCRF as either ‘normal’ or ‘abnormal’. If 
‘abnormal’, a comment must be given together with an assessment of clinical significance (yes/no).  
Abnormal, clinically significant findings at screening should be recorded as concomitant illness in 
the eCRF. At the following visits, any new abnormal, clinically significant findings or clinically 
significant deteriora tions from baseline should be reported as an AE (See Appendix 3, 
Section  10.3). 
Body measurements (e.g. height and weight) will be measured and record ed as specified in the 
flowchart 1.2  
• Body weight should be measured in kilogram (kg) or pounds (lb). Body weight will be 
recorded to one decimal.  
• Height should be measured in centimetres (cm) or inches (in) at screening visit ( V1) without 
shoes. Height will be recorded to the nearest whole number.  
8.2.3 Vital signs  
• Pulse rate, as well as systolic and diastolic blood pressure will be assessed as specified in the 
flowchart 1.2. 
• Manual techniques must be used only if an automated device is not available.  
• Blood pressure and pulse rate at V1 and V6 will consist of [ADDRESS_927128] two readings on systolic or diastolic 
blood pressure differ by >[ADDRESS_927129] be recorded in the eCRF.   
• Pulse rate will be measured in connection to the blood pressure measurements. Record the 
pulse rate for the last [ADDRESS_927130] 2 measurements.  
8.2.4 Electrocardiograms  
• A [ADDRESS_927131] be performed by [CONTACT_111418] ( 1.2). 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 37 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  38 of 89 
 
   
 • The ECG should be preceded by [CONTACT_2669] [ADDRESS_927132] in a supi[INVESTIGATOR_050]/sitting 
position in a quiet setting without distractions (e.g. no use of television, cell phones).  
• The ECG must be interpreted, signed and dated by [CONTACT_41152] .  
• The ECG required at screening can be obtained within [ADDRESS_927133].  
• The ECG required at V4 and the end of treatment (V6) visit can be obtained within [ADDRESS_927134] be available for evaluation at the visit.  
• Abnormal, clinically signific ant findings at screening should be recorded as concomitant 
illness in the eCRF. At the following visits, any new abnormal, clinically significant 
findings or clinically significant deteriorations from baseline should be reported as an AE 
(see Appendix 3, Section 10.3).  
8.2.[ADDRESS_927135] or another suitably qualified health 
care provider (e.g. optometrist) mu st be available and evaluated by [CONTACT_684311]. The eye examination should be performed as a fundus photography (e.g. 2 -field 60 
degree or better, colour or red -free) or by [CONTACT_41157] -lamp biomicroscopy examination (e.g. using a pre -
corne al or corneal contact [CONTACT_41158]). Pharmacological pupil -dilation is a requirement unless 
using a digital fundus photography camera specified for non -dilated examination.  
If the subject had such an eye examination performed within 90 days prior to sc reening, the 
investigator may base his/her evaluation upon the results of that examination. The examination must 
be repeated before randomisation if the subject has experienced worsening of visual function since 
the last examination. If the applicable eye examination was performed before the subject signed the 
informed consent form, it must be documented that the reason for performing the examination was 
not related to this trial.  
Eye examinations required at the end of treatment (V6) visit can be performed  within [ADDRESS_927136] be recorded as concomitant illness/medical history. While relevant findings 
occurring after randomisation should be reported as an AE, please refer to Appendix 3 
(Section  10.3). 
8.2.6 Clinical safety laboratory assessments  
All protocol -required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the flowchart and laboratory manual . 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 38 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927137] and/or investigational medical device 
AE or SAE.   
Investigators should train subjects to contact [CONTACT_684312] e events.  
The definition of AEs and SAEs can be found in Appendix 3 and Appendix 6 (Section 10.3 and 
Section 10.6), along with a description of AEs for adjudication and  AEs requiring additional data 
collection.  
All AEs and investigational medical device deficiencies (DoseGuide System) that could have led to 
an SAE are reportable, see Appendix 5, (Section 10.5). 
All AEs occurring in subjects randomised to icodec require completion of specific adverse event 
investigational medical device form (Appendix 6, Section 10.6). 
In addition, some AEs require additional data collection on a specific event form. This includes  
medication error, misuse and abuse of IMP. The relevant events are listed below in Table  8-1.  
AEs for adjudication require data collection on an adjudication form. Event adjudication will be 
performed in randomised subjects and will be evaluated by [CONTACT_684313] (EAC) in a blinded manner, please refer to Section [IP_ADDRESS] .   
Refer to Appendix 3 (Section 10.3) and Appendix 6 (Section 10.6)for further details on reportable 
adverse events and reporting timelines ( Figure  10-1).  
Hypoglycaemic epi[INVESTIGATOR_364041] a hypoglycaemic epi[INVESTIGATOR_684279]. Non -serious hypoglycaemic epi[INVESTIGATOR_684280]. If the hypoglycaemic epi[INVESTIGATOR_197620], then, in addition to the 
hypoglycaemic epi[INVESTIGATOR_364044], an AE form  and a safety information form must be completed in the 
eCRF, please refer to Appendix 3 (Section  10.3). If a non -serious hypoglycaemic epi[INVESTIGATOR_684281] a DoseGuide System technical complaint, this should be reported along with the technical 
complaint, please refer to Appendix 5 (Section 10.5) For more information on hypoglycaemic 
epi[INVESTIGATOR_1841], please refer to Appendix 8 (Section 10.8). 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 39 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  40 of 89 
 
   
 Table  8-1 AEs requiring additional data collection (serious and non -serious AEs), and 
events for adjudication   
Event type   AE requiring additional 
data collection  Event for adjudication  
 
Medication error  X  
Misuse and abuse  X  
Acute coronary syndrome (acute myocardial 
infarction (MI) or unstable angina pectoris 
requiring hospi[INVESTIGATOR_11956])   X 
Cerebrovascular events* (stroke or transient 
ischemic attack)   X 
Heart failure (requiring hospi[INVESTIGATOR_111355])   X 
Death   X 
Hypersensitivity  X  
Injection site reaction  X  
*All cerebrovascular events are to be reported and sent for adjudication, however the EAC will only confirm strokes.  
A detailed  description of the events mentioned in the above table can be found in Appendix  3 
(Section  10.3.3 ). 
Events for Adjudication  
There are four ways to identify events relevant for adjudication as described below:  
• Investigator -reported events for adjudication: investigator selects the appropri ate AE 
category relevant for adjudication (see Appendix 3, Section 10.3.3 ).   
• AEs reported with fatal outcome  
• AE search (standardised screening): All  AEs not reported with an AE category relevant for 
adjudication will undergo screening to identify potential events for adjudication. 
Investigators will be notified of these events in the eCRF.  
• EAC -identified events: Unreported events relevant for adjudic ation identified by [CONTACT_111421].  
Investigators will be notified of these events in the eCRF and has the option to report the 
EAC -identified event.   
For each event relevant for adju dication an event type specific adjudication form should be 
completed in the eCRF within 14 days.  
Copi[INVESTIGATOR_111356] (EAS) as soon as 
possible and preferably within 4 weeks. In cases where the EA S is not accessible the investigator 
should ensure that the relevant source documents are collected and saved locally until the EAS is 
ready. If no, or insufficient source documents are provided to the adjudication supplier, the 
investigator can be asked t o complete a clinical narrative to be uploaded to the EAS.  
If new information becomes available for an event sent for adjudication, it is the responsibility of 
the investigator to ensure the new information is uploaded to the EAS.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 40 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927138] also be collected from V8 until the Early Discontinuation 
Follow -up visit (V6A).  
Medical occurrences that take place or have onset prior to the time point from which AEs are 
collected will be recorded as concomitant illne ss/medical history. AE and SAE reporting timelines 
can be found in Appendix 3 (Section 10.3) for the IMP and Appendix 6 (Section 10.6) for the 
investigational medical device. All SAEs must be recorded and reported to Novo Nordisk within [ADDRESS_927139] has been 
discont inued from/completed the trial, and the investigator considers the event to be 
possibly/probably related to the trial product or related to trial participation, the investigator must 
promptly notify Novo Nordisk.  
8.3.2 Method of detecting AEs and SAEs  
The method  of recording, evaluating and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3) for the IMP 
and Appendix 6 (Section 10.6) for the investigational medical device.  
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of the subject is the preferre d method to inquire about events.  
8.3.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs,  should be followed until final outcome of the event or the  
subject is lost to follow -up as described in Section 7.3. Further information on follow -up and final 
outcome of events is given in Appendix 3 (Section  10.3) for IMP and Appendix 6 (Section 10.6) for 
the investigational medical device.  
8.3.[ADDRESS_927140] under clinical investigation. Novo Nordisk 
will comply with country -specific regulatory requirements relating to safety reporting to the 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 41 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  42 of 89 
 
   
 regulatory authority, IRB/IEC, and investigators. This also includes suspected un expected serious 
adverse reaction (S[LOCATION_003]R) (for IMP) and unanticipated serious adverse device effect ([LOCATION_003]DE) (for 
the investigational medical device).  
An investigator who receives an investigator safety report describing a SAE or other specific safety 
infor mation (e.g. summary or listing of SAEs) from Novo Nordisk will review and then file it along 
with the investigator's brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.  
8.3.[ADDRESS_927141] becomes pregnant, the investigator should inform Novo Nordisk within 14 
calendar days of learning of the pregnancy and should follow the procedures outlined in Appendix  4 
(Section 10.4). 
8.3.6 Cardiovascular and death events  
Cardiovascular and death events will be handled and reported according to Section 8.3. 
8.3.7 Technical complaints  
Technical complaints will be collected for all products listed on the technical complaint form. 
Instructions for reporting technical complaints can be found in Appendix 5 (Section 10.5). 
In order for Novo Nordisk to perform a complete investigation of reported SAEs, Novo Nordisk 
might ask the investigator to complete a technica l complaint form.   
8.[ADDRESS_927142] be reported 
as misuse and abuse, please refer to Section 8.3 and Appendix 3 (Section 10.3) for further details.  
In the event of an overdose, the investigator should closely monitor the subject for overdose -related 
AE/SAE and laboratory abnormalities until the blood glucose is norma lised and (or) 
signs/symptoms have been relieved.  
A specific overdose for insulin icodec cannot be defined; however, hypoglycaemia may develop 
over sequential stages if the doses administered are too high relative to the subject’s requirements.  
• Mild hypo glycaemia can be treated by [CONTACT_41147].  
• Severe hypoglycaemia, where the subject is not able to treat him/herself, can be treated by 
[CONTACT_41148] (0.5 to 1 mg) given i.m. or s.c. by a trained person, or by [CONTACT_111422] i .v. by a 
medical professional. Glucose must also be given i.v., if the patient does not respond to 
glucagon within [ADDRESS_927143] upon regaining consci ousness, in order to 
prevent a relapse.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 42 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927144] . 
For more information on overdose, also consult the current version of the insu lin icodec 
investigator's brochure  and any updates hereof .  
Treatment for overdose of once daily basal insulin analogues should be at the discretion of the 
investigator and per standard care, for more information, consult the current version  and any 
update s hereof  of the Investigator’s Brochure, EMA Summary of Products Characteristics (SmPC), 
US Prescribing Information or locally approved Product Information for the relevant product.  
8.[ADDRESS_927145] signs and symptoms of systemic 
hypersensitivity. In the event of a systemic hypersensitivity (not locally at the injection site), the 
patient should be called in as soon as possible to have additional  blood samples taken in order to 
analyse the following parameters:  
• Tryptase (optimal 0.[ADDRESS_927146] the hypersensitivity reaction)  
• Total immunoglobulin E (IgE) antibodies  
• Anti-insulin icodec IgE antibodies   
• Anti-insulin icodec binding antibodies  
• Anti-human insulin IgE antibodies  
The blood sampling should be repeated [ADDRESS_927147] 
administration of trial drug.  
For details related to blood sampling, plasma preparation and storage, please refer to the laboratory 
manual.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 43 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  44 of 89 
 
   
 Analysis will be performed by [CONTACT_49705] a Novo Nordisk appointed special laboratory 
(please refer to Attachment I ). The results will be reporte d in a separate report and attached to the 
CTR.  
For retention of residual hypersensitivity samples, please refer to  Appendix 7,  Section 10.6. 
Digital  pi[INVESTIGATOR_364045], using any device available (mobile phone, camera etc.) and thereafter as often as 
judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_684282], 
date and time, time after dosing and a ruler for scaling. All pi[INVESTIGATOR_111358].  
8.10 Health economics  
Not relevant for this trial.  
9 Statistical considerations   
9.1 Statistical h ypotheses  
The primary hypothesis to be tested is that insulin icodec used with DoseGuide is non -inferior to 
once daily basal insulin analogues in terms of change from baseline to week 52 in HbA 1c. 
Formally, let D be the treatment difference ‘insulin icodec  used with DoseGuide’ minus ‘basal 
insulin analogues’ of the change in HbA 1c from baseline to week 52. The null -hypothesis will be 
tested against the alternative hypothesis of non -inferiority as given by  
H0: D≥0.30% against HA: D <0.30%  
The non -inferiorit y margin of 0.3% -point is chosen based on the recommendation in the FDA 
guidance for industry on developi[INVESTIGATOR_111359].19 Also, this margin is 
considered to provide sufficient assay sensitivity based on the bel ow considerations:  
• The margin does not represent an unacceptable loss of efficacy with insulin icodec relative to 
treatment with a basal insulin analogue  
• It represents less than 50% of a suitably conservative estimate of insulin glargine’s treatment 
effect  on HbA 1c in a placebo -controlled trial in insulin naïve subjects ( -0.85% -point [ -1.04; -
0.66] 95%CI versus placebo), which demonstrated insulin glargine’s superiority20. 
• Other basal insulin analogues have previously been shown to yield similar reductions in HbA 1c 
compared to insulin glargine.  
The following describes the secondary confirmatory hypothesis. In order to control the overall Type 
I error at a 5% level, two sided, a hierarchical testing procedure will be used. If non -inferiority in 
glycaemic control is concluded in the primary analysis, confirmatory testing proceeds to the 
following hypothesis:  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 44 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  45 of 89 
 
   
 • Insulin icodec used with DoseGuide is superior to once daily basal insulin analogues in 
terms of change in HbA1c from baseline to week 52  
Formally, let D be the mean treatment difference ‘insulin icodec used with Dose Guide’ minus 
‘basal insulin analogues’ of the change in HbA 1c from baseline to week 52. The null -hypothesis of 
insulin icodec used with DoseGuide not superior will be tested against the alternative hypothesis of 
superiority as given by:  
H0: D≥0.0% against HA: D <0.0%  
9.[ADDRESS_927148] 90% power for declaring non -inferiority with a non -
inferiority margin of 0.3% -point with respect to change in HbA 1c for the specified estimand and the 
full analysis set ( primary analysis set). Based on CONFIRM, a trial that compared the real -world 
effectiveness of insulin degludec and glargine U300 in insulin -naïve subjects with T2D in routine 
US clinical practice, and market analytics on retention and switching from a bas al insulin, it is 
expected that approximately 30% of insulin naïve subjects initiating insulin treatment will 
discontinue from their assigned insulin treatment within [ADDRESS_927149] to a basal -bolus 
treatment regimen.  
In the phase 3 randomised clinical trial (RCT) setting with a treat -to-target approach, the SD of 
HbA 1c after 12 months of treatment with a basal insulin has previously been observed to be 1.0% or 
less (NN1250, NN9068). In -the Explorys, a database of electronic medical records representing 39 
integrated healthcare -delivery networks in the US, the SD for HbA 1c 12 months (+/ - 90 days) after 
insulin initiation was 1.9 % in T2D subjects no t being treated with an insulin for at least [ADDRESS_927150] of 
the increase that was seen in the Explorys database. I.e., the SD for the present trial is assumed to be 
1.3%.  
A treatment difference of 0.0% -point in subjects co mpleting 52 weeks of treatment is expected. It is 
further conservatively assumed that the treatment difference will be 0.15% -point in favour of basal 
insulin analogues for subjects discontinuing randomised treatment prior to week 52. Accounting for 
treatme nt discontinuation, an adjusted treatment difference of 0.045% -point in favour of basal 
insulin analogues is therefore expected for the estimand.  
The trial should be powered to be able to demonstrate non -inferiority of insulin icodec used with 
DoseGuide ve rsus once daily basal insulin analogues as well as having reasonable power to detect a 
treatment difference of 0.3% -point in favour of insulin icodec used with DoseGuide in all 
randomised as being statistically significant different from 0.0% -point for the  primary endpoint of 
change in HbA 1c from baseline to week 52.  
From the above assumptions and requirements, [ADDRESS_927151].  
This will ensure sufficient power (90%) of confirming non -inferiority while also having sufficient 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 45 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  46 of 89 
 
   
 marginal power (97%) to detect a treatment difference of 0.3 %-point in favour of insulin icodec 
used with DoseGuide in all randomised as being statistically significant different from 0.0% -point.  
With an expected screening failure rate of 9%, approximately [ADDRESS_927152] deviations  
SD 
(%-point)  
  
 
0.03 Treatment difference  
(%-point)  
0.045   
 
0.06 
1.2 96% 94% 91% 
1.3 93% 90%  86% 
1.4 89% 85% 81% 
SD: standard deviation. Power is computed for 1:1 randomisation and 1096 subjects randomised.  
9.3 Populations for analyses  
The following populations  are defined : 
Population  Description  
Randomised  All subjects randomised  
Full analysis set  Full analysis set (FAS): All subjects randomised. Subjects will be analysed 
according to the randomised treatment.  
Safety  analysis set  All subjects randomly assigned to trial treatment and who take at least [ADDRESS_927153]. Subjects are analysed according to the treatment they actually 
received.  
In exceptional cases, subjects or observations may be eliminated from the full analysis set. In such 
case the reasons for their exclusion will be documented before unblinding. The subjects and 
observatio ns excluded from analysis sets, and the reason for this, will be described in the clinical 
trial report (CTR).  
The following periods will be considered for the data collected:  
In-trial period  
The in -trial period starts at randomisation and ends at the date  of: 
• The last direct subject -site contact  
• Withdrawal for subjects who withdraw their informed consent  
• The last subject -investigator contact [CONTACT_135556] -up (i.e. possibly an unscheduled phone visit)  
• Death for subjects who die before any of the above  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 46 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927154] date of any of the following:  
• The end of trial visit (V8)  
• The last date on trial product + 5 weeks for once daily insulin and + 6 weeks for once 
weekly in sulin (corresponding to 5 weeks after the end of the dosing interval for both 
treatment arms)  
• The end -date for the in -trial observation period  
The on -treatment period represents the time period in which a subject is considered exposed to trial 
product.  
All efficacy endpoints will be summarised and analysed using the full analysis set (FAS) and the 
‘in-trial’ period. Safety endpoints will be evaluated using the on -treatment period with descriptive 
statistics being based on the safety analysis set (SAS) an d statistical analyses being based on the 
FAS unless otherwise specified.  
9.4 Statistical analyses  
The statistical analysis plan (SAP) will be finalised prior to first subject first visit, and it will 
include a more technical and detailed description of the st atistical analyses described in this section.  
This section is a summary of the planned statistical analyses of the most important endpoints 
including primary and secondary endpoints.  
9.4.1 General considerations  
Presentation of results from a statistical analysi s will include the estimated mean treatment 
difference (or ratio) presented together with the two -sided 95% confidence interval and the 
corresponding two -sided p -value.  
In the statistical models, explanatory factors will be coded as follows:  
• Treatment: Onc e weekly insulin icodec used with DoseGuide, basal insulin analogues  
• Region: Europe, North America  
The regions will be defined as follows:  
• Europe: [LOCATION_013], Greece, Hungary, Poland, Serbia, Turkey  
• North America: Canada, [LOCATION_002]  
The last available assessment made prior to the first dose will be used as the baseline value.  
9.4.2 Primary endpoint  
The primary endpoint is change in HbA 1c from baseline to week 52.  
The ‘treatment policy’ estimand will be estimated based on the full analysis set using all HbA 1c 
measurements obtained at the week 52 visit, especially including measurements from subjects 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 47 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  48 of 89 
 
   
 discontinuing their randomised treatment. Missing HbA 1c at the week 52 visit (regardless of 
treatment completion status) will be imputed from trial participants, w ho have discontinued their 
randomised treatment prior to the week [ADDRESS_927155]:  
• First, one thousand (1000) copi[INVESTIGATOR_364046] 1c.  
• Second, for subjects who discontinu ed their randomised treatment at any time prior to the 
week [ADDRESS_927156] available planned on -treatment (LAOT) value to the week 52 visit will be analysed 
for each dataset copy using an analysis of covariance (ANCOVA) model with randomised 
treatment as fixed factor and LAOT value and the time point (study day) of this assessment 
as covariates. The estimated parameters, and their variances, from the model will be used to 
impute mi ssing HbA 1c values for the change from LAOT to the week 52 visit and 
subsequently the missing HbA 1c value at the week 52 visit.  
• For each of the complete data sets, the primary endpoint will be analysed using an 
ANCOVA model with region and randomised treat ment as fixed factors, and baseline HbA 1c 
as a covariate. The estimates and standard deviations for the [ADDRESS_927157] deviation using Rubin’s rule21. 
This analysis has the underlying assumption that subjects with missing data behave similarly as 
subjects that discontinue randomised treatment.  
If non -inferiority is confirmed, i.e. if the 95% CI is strictly below 0.3%, then the primary endpoint 
will further be tested for superiority. Superiority for change in HbA 1c will be considered confirmed 
if the 95% CI is strictly below zero.  
The following sensitivity analysis evaluating the robustness of the assumptions about the missing 
data will be carried out:  
For the primary endpoint, a two -dimensional tippi[INVESTIGATOR_684283] 1c measurement at the week [ADDRESS_927158] a worse 
outcome in the insulin icodec used with DoseGuide arm and a better outcome in the basal insulin 
analogues arm compared to what was imputed in the primary analysis. This is done by [CONTACT_684314] Δ i to the imputed HbA 1c values before analysing the data. The value of Δ i will be 
varied independently in  the two treatment arms. The non -inferiority margin of 0.3% will be among 
the Δi values investigated. The plausibility of the values of Δ i where the conclusion of the primary 
analysis change will be evaluated to assess the robustness of the primary analysi s result.  
9.4.3 Secondary endpoints  
[IP_ADDRESS]  Supportive secondary endpoints  
Supportive secondary endpoints will be evaluated in the framework of the primary estimand.  
Efficacy endpoints  
Time from baseline to treatment discontinuation or intensification (from baseline week 0 (V2) to 
week 52 (V6))  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 48 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927159] to 
follow -up or withdrawing from trial before the completion of the treatment period will contribute to 
the analysis as discontinuing treatment at the time of the end of the in -trial period if the time of 
discontinuation is unknown. Cumulative incidence function by [CONTACT_684315] (risk ratio) at week 26 and week 52. The 25%, 
50% (median) and 75% percentiles based on the cumulative incidence function will also be 
presented. For details on additional analyses, please ref er to SAP.  
Change in DTSQs (Diabetes Treatment Satisfaction Questionnaire) in total treatment 
satisfaction from baseline week 0 (V2) to week 52 (V6)  
Missing DTSQs scores in total treatment satisfaction at the week 52 visit (regardless of treatment 
completi on status), will be imputed from trial participants who are from the basal insulin analogues 
group, and who have completed and adhered to their randomised insulin treatment – i.e., data will 
be imputed based on the assumption that subjects with missing end point data will behave like 
subjects completing the treatment with basal insulin analogues. Specifically, the imputations will be 
carried as follows:  
• First, one thousand (1000) copi[INVESTIGATOR_684284].  
• Second, for each dataset copy, an analysis of covariance (ANCOVA) model with a baseline 
value as a covariate will be fitted to DTSQs scores in total treatment satisfaction for subjects 
who completed their randomised treatment in the basal insulin analogues group. The 
estimated mean, and variances, from the model will be used to impute missing values in 
both treatment groups.  
• For each of the complete data sets, the endpoint will be analysed using an ANCOVA model 
with region and randomised tr eatment as fixed factors and a baseline value as a covariate. 
The estimates and standard deviations for the [ADDRESS_927160] deviation using Rubin’s rule.  
Trim -D (Treatment Related Impact Measure for Dia betes) compliance domain at week 52 (V6)  
Trim -D compliance domain at week 52 will be analysed using the same model as specified for 
change in DTSQs in total treatment satisfaction, but without using the baseline value as a covariate.  
Safety endpoints  
Hypog lycaemic epi[INVESTIGATOR_111363]:  
• Number of severe hypoglycaemic epi[INVESTIGATOR_1841] (level 3) from baseline week 0 (V2) to week 57 
(V8)  
• Number of clinically significant hypoglycaemic  epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 
mg/dL), confirmed by [CONTACT_41132]) from baseline week 0 (V2) to week 57 (V8)  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 49 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  50 of 89 
 
   
 • Number of clinically significant hypoglycaemic epi[INVESTIGATOR_1841] (level 2) (<3.0 mmol/L (54 
mg/dL), confirmed by [CONTACT_41132]) or severe hypoglycaemic epi[INVESTIGATOR_1841]  (level 3) from baseline 
week 0 (V2) to week 57 (V8)  
For subjects who discontinued their randomised treatment, the number of epi[INVESTIGATOR_684285] (time of follow -up 2 (V8) to planned end of the on -treatment period) will be imputed using a 
multipl e imputation technique, assuming that the event rate pre follow -up 2 (V8) follows the 
respective treatment groups rate whilst post follow -up 2 (V8) event rate is the rate of the basal 
insulin analogues group. The imputation will be done as follows:  
• First, a Bayes negative binomial model with log -link function will be fitted to the event rate 
data to obtain the posterior distribution of model parameters. The model will include region 
and randomised treatment as fixed factors and the logarithm of the on -treatment period as 
offset.  
• Second, based on the estimated parameters for the basal insulin analogues group in this 
model, the number of epi[INVESTIGATOR_684286]. Multiple copi[INVESTIGATOR_014] (10 00 copi[INVESTIGATOR_014]) of a complete data 
set will be generated by [CONTACT_111424].  
• For each of the complete data sets, the number of epi[INVESTIGATOR_111366] a negative 
binomial model with log -link, fixed factors and offset as describ ed in step 1. The estimates 
and SDs for the 1000 data sets will be pooled to one estimate and associated SD using 
Rubin’s rule.  
For the definition and classification of hypoglycaemic epi[INVESTIGATOR_111367] 8  (Section 10.8). 
For details on analyses of additional supportive secondary endpoints, please refer to the SAP.  
9.4.[ADDRESS_927161] safety assessments (SAEs, 
AEs, safety laboratory parameters, vital signs, etc.) will be reported descriptively based on the 
on-treatment perio d; including any notable changes of clinical interest in laboratory parameters. In 
addition, SAEs will be reported descriptively based on the in -trial period.  
9.4.6 Other analyses  
For other analyses,  please refer to the SAP.   
9.5 Interim analyses  
Not applicable for  this trial.  
9.6 Data monitoring committee  
Not applicable for this trial.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 50 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  51 of 89 
 
   
 9.7 Reporting of the main part of the trial  
Not applicable for this trial.  
10 Supporting documentation and operational considerations  
10.1 Appendix 1 : Regulatory, ethical, and trial oversight considerations  
10.1.1  Regulatory and ethical considerations  
• This trial will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki22 and applicable ICH Good Clinical Practice (GCP) Guideline23 and ISO 
1415512 
• Applicable laws and regulations  
• The protocol, informed consent form, investigator’s brochure (as applicable) and other 
relevant documents (e.g. advertisements) must be submitted to an IRB/IEC and reviewed 
and approved by [CONTACT_1201]/IEC before the trial is initiated.  
• Regulatory authorities w ill receive the clinical trial application, protocol amendments, 
reports on SAEs, and the CTR according to national requirements.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except  for changes necessary to eliminate an immediate 
safety hazard to trial subjects.  
• Before a site is allowed to start screening subjects, written notification from Novo Nordisk 
must be received.  
• The investigator will be responsible for:  
o providing written sum maries of the status of the trial annually or more frequently in 
accordance with the requirements, policies, and procedures established by [CONTACT_5040]/IEC and/or regulatory authorities  
o notifying the IRB/IEC of SAEs or other significant safety findings as requi red by 
[CONTACT_1744]/IEC procedures  
o providing oversight of the conduct of the trial at the site and adherence to 
requirements of ICH guidelines, the IRB/IEC, and all other applicable local 
regulations  
o ensuring submission of the CTR synopsis to the IRB/IEC  
o reporting any potential serious breaches to the sponsor immediately after discovery  
10.1.[ADDRESS_927162] igators and sub -investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of  the trial.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 51 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  52 of 89 
 
   
 10.1.3  Informed consent process  
• The investigator or his/her representative will explain the nature of the trial to the subject 
and answer all questions regarding the trial.   
• The investigator must ensure the subject ample time to come to a decision whe ther or not to 
participate in the trial.   
• Subjects must be informed that their participation is voluntary.  
• Subjects must be informed about their privacy rights.  
• Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines23, Declaration of Helsinki22, ISO  1415524 
and the IRB/IEC or site.  
• The medical record must include a statement that written informed consent was obtained 
before any trial related activity and the date when the written consent was obtained. The 
authorised person obtaining t he informed consent must also sign and date the informed 
consent form before any trial related activity.  
• The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may delegate the task to a medically qualified p erson, in accordance with local 
requirements.  
• Subjects must be re -consented to the most current version of the informed consent form (s) 
during their participation in the trial.  
• A copy of the informed consent form (s) must be provided to the subject.  
10.1.[ADDRESS_927163] may 
receive a “welcome to the trial letter” and a “thank you for your participation letter” after 
completion of the trial. Further, the subject may receive other written information during th e trial.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950] . 
10.1.5   Data protection  
• Subjects will be assigned a [ADDRESS_927164] are transferred to Novo Nordisk.  
• The subject and any biological material obtained fr om the subject will be identified by 
[CONTACT_18022], visit number and trial ID. Appropriate measures such as encryption or 
leaving out certain identifiers will be enforced to protect the identity of subjects as required 
by [CONTACT_5737], regional and national requ irements.   
• The subject must be informed about his/her privacy rights, including that his/her personal 
trial related data will be used by [CONTACT_18023]. 
The disclosure of the data must also be explained to the sub ject.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 52 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  53 of 89 
 
   
 • The subject must be informed that his/her medical records may be examined by [CONTACT_18024], by [CONTACT_6667]/IEC members, 
and by [CONTACT_6668].  
10.1.6  Committees structure  
[IP_ADDRESS]  Novo N ordisk safety committee  
Novo Nordisk will perform ongoing safety surveillance. If new safety signals are identified, these 
will be evaluated by [CONTACT_18025].  
[IP_ADDRESS]  Data monitoring committee  
Not applicable for this trial.  
[IP_ADDRESS]  Event adjudication comm ittee 
An independent external EAC is established to perform ongoing blinded adjudication of selected 
AEs and deaths (see  Table  8-1). 
The EAC will evaluate events sent for adjudication using pre -defined definitions and guidelines in 
accordance with the EAC charter. The evaluation is based on review of pre -defined clinical data 
collected by [CONTACT_30107]. The EAC is composed of permanent members covering all required medical 
specialities. EAC members must disclose any potential conflicts of interest and must be independent 
of Novo Nordisk. The EAC will have no authority to impac t trial conduct, trial protocol or 
amendments. The assessments made by [CONTACT_364069].   
10.1.7  Dissemination of clinical trial data  
Information of the trial will be disclosed at  clinicaltrials.gov and novonordisk -trials.com. It will also 
be disclosed according to other applicable requirements, such as those of the International 
Committee of Medical Journal Editors (ICMJE)25, the Food and Drug Administration Amendment 
Act (FDAAA)26, European Commission Requirements27-[ADDRESS_927165] at 
these websites, Novo Nordisk may disclose the investigator’s contact [CONTACT_684316]. As a 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.  
The primary completion date (PCD) is the last assessment of the primary endpoint, and is for this 
trial last subject first treatment  (LSF T) + [ADDRESS_927166] completed visit 
V6. The PCD determines the deadline for results disclosure at clin icaltrials.gov according to 
FDAAA.  
10.1.8  Data quality assurance  
[IP_ADDRESS]  Case report forms  
• Novo Nordisk or designee is responsible for the data management of this trial including 
quality checking of the data.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 53 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  54 of 89 
 
   
 • All subject data relating to the trial will be recorded on ele ctronic CRFs (eCRFs)  unless 
transmitted electronically to Novo Nordisk (e.g. laboratory, DoseGuide System data and 
eDiary  data) or when applicable on paper CRF. The investigator is responsible for verifying 
that data entries are accurate and correct by [CONTACT_684317].  
• The following will be provided as paper CRFs:  
o Pregnancy forms  
• The following will be provided as paper CRFs to be used when access to the eCRF is 
revoked or the eCRF is temporarily unavailable:  
o AE forms   
o Safety information forms  
o Technical complaint forms (also to be used to report complaints on trial product not 
yet allocated to a subject)  
o Device deficiency that could have led to an SAE form  
• Corrections to the CRF data may be made by [CONTACT_684318]’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the 
old and the new data, identification of the person entering the data, date and time of the 
entry and reason for the correction. If corrections  are made by [CONTACT_093]’s delegated 
staff after the date when the investigator signed the CRF, the CRF must be signed and dated 
again by [CONTACT_093].  
• The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to 
Novo Nordisk for data verification and validation purposes.   
[IP_ADDRESS]  Monitoring  
• The investigator must permit trial -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents (original 
documents, data and records). Direct access includes permission to examine, analyse, verify 
and reproduce any record(s) and report(s) that are important to the evaluation of th e trial. If 
the electronic medical record does not have a visible audit trail, the investigator must 
provide the monitor with signed and dated printouts. In addition, the relevant site staff 
should be available for discussions at monitoring visits and betw een monitoring visits (e.g. 
by [CONTACT_756]).   
• Trial monitors will perform ongoing source data verification to confirm that data entered 
into the eCRF by [CONTACT_18029], complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is 
being conducted in accordance with the currently approved protocol and any other trial 
agreements, ICH GC P, and all applicable regulatory requirements.  
• Monitoring will be conducted using a risk -based approach including risk assessment, 
monitoring plans, centralised monitoring (remote assessment of data by [CONTACT_3454]) and 
visits to sites.   
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 54 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  55 of 89 
 
   
 • Monitors will revi ew the subject’s medical records and other source data, to ensure 
consistency and/or identify omissions compared to the eCRF.  
[IP_ADDRESS]  Protocol compliance  
Deviations from the protocol should be avoided. If deviations do occur, the investigator must 
inform the moni tor without delay and the implications of the deviation must be reviewed and 
discussed.  
Deviations must be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not  possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the trial database.   
10.1.[ADDRESS_927167] be verifiable in source documentation, except for the 
following data that has been transferred directly into the database and will be considered source 
data:  
• Data in the service providers’ database e.g. ePROs, eDiary data and DoseGuide System 
data, is considered source data.  
• Source documents provide evidence for the existence of the sub ject and substantiate the 
integrity of the data collected. Source documents are filed at the site.  
• Data reported on the paper CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents, or the discrep ancies must be 
explained. The investigator may need to request previous medical records or transfer 
records. Also, current medical records must be available.   
• It must be possible to verify subject’s medical history in source documents, such as subject’s 
medical record  
• The investigator must document any attempt to obtain external medical information by 
[CONTACT_18031](s) when information was requested, and who was contact[INVESTIGATOR_530].  
• Definition of what constitutes source data can be found in a source document agreem ent at 
each site. There will only be one source document defined at any time for any data element.  
10.1.10  Retention of clinical trial documentation  
• Records and documents, including signed informed consent forms, pertaining to the conduct 
of this trial must be ret ained by [CONTACT_1732] 15 years after end of trial unless local 
regulations or institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No 
records  may be transferred to another location or party without written notification to Novo 
Nordisk.   
• The investigator must be able to access his/her trial documents without involving Novo 
Nordisk in any way. If applicable, electronic CRF (eCRF) and other subjec t data will be 
provided in an electronic readable format to the investigator before access is revoked to the 
systems  supplied by [CONTACT_3454]. Site -specific CRFs and other subject data (in an 
electronic readable format or as paper copi[INVESTIGATOR_17951]) must be  retained by [CONTACT_779]. A copy 
of all data will be stored by [CONTACT_3454].  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 55 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  56 of 89 
 
   
 • Subject’s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.  
10.1.[ADDRESS_927168] 
inform the subjects promptly and ensure appropriate therapy and follow -up. The investigato r and/or 
Novo Nordisk must also promptly inform the regulatory authorities and IRBs/IECs and provide a 
detailed written explanation.  
Sites will be closed upon trial completion. A site is considered closed when all required documents 
and trial supplies have  been collected and a site closure visit has been performed.  
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a site by [CONTACT_41177]:  
• failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, Novo Nordisk procedures or GCP guidelines  
• inadequate recruitment of subjects by [CONTACT_093]  
• discontinuation of further trial product development.  
10.1.[ADDRESS_927169] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial  at the site. If any tasks are delegated, the investigator must 
maintain a log of appropriately qualified persons to whom he/she has delegated specified trial -
related duties. The investigator must ensure that there is adequate and documented training for a ll 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to protect the rights, safety, and well -being of the subjects.   
A qualified physician, who is an investigator or a sub inv estigator for the trial, must be responsible 
for all trial -related medical decisions.   
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be kept in a secure locked facility so that no unauthorized persons can get access to 
the data.   
The investigator wi ll take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicabl e law. The investigator 
must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safety measures have been taken.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 56 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927170] delegate r esponsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.  
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new inves tigator will be appointed in consultation with Novo Nordisk.   
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).  
10.1.[ADDRESS_927171] liability for its products, a nd liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.   
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by [CONTACT_18033].   
10.1.[ADDRESS_927172], if deemed necessary by [CONTACT_3454]. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during this trial to researchers who re quire access for research projects studying the same 
disease and/or trial product studied in this trial.  
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.  
One or two investigators will be appointed by [CONTACT_684319] (signatory 
investigator) on behalf of all participating investigators.   
[IP_ADDRESS]  Communication of results  
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes publication of a manuscript  in a peer -reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by [CONTACT_11174].   
The results of this trial will be subject to public disclosure on external web sites according to 
internat ional and national regulations. Novo Nordisk reserves the right to defer the release of data 
until specified milestones are reached, for example when the CTR is available. This includes the 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 57 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  58 of 89 
 
   
 right not to release the results of interim analyses, because the release of such information may 
influence the results of the entire trial.  
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone pub lication and/or 
communication for up to [ADDRESS_927173] intellectual property.  
In all cases, the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. In the event of any disagreement on the 
content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_17952].  
[IP_ADDRESS]  Authorship  
Novo Nordisk will work with one or more investigator(s) and other experts who h ave contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in one 
or more publications.  
Authorship of publications should be in accordance with the Recommendations for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by [CONTACT_18037].30 
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned publication.   
Where required by [CONTACT_445001], the investigator from each site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038].   
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s)  
For a multicentre clinical trial, analyses based on single -site data us ually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should always reference the primary manuscrip t of the trial.  
[IP_ADDRESS]  Investigator access to data and review of results  
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database.  
Individual investigators will have their own research subjects’ data and wi ll be provided with the 
randomisation code after results are available.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 58 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  59 of 89 
 
   
 10.2 Appendix 2: Clinical laboratory tests  
• The tests detailed in Table  10-1 and Table  10-2 will be performed by [CONTACT_2237].  
• Additional tests may be perfo rmed at any time during the trial as determined necessary by 
[CONTACT_11006]. Only laboratory samples specified in the 
protocol should be sent to the central laboratory for analysis; if additional laboratory 
sampling is ne eded, e.g. to follow -up on AEs, this must be done at a local laboratory.  
• The central lab will communicate to the investigator abnormal values of parameters not 
requested in the protocol but identified by [CONTACT_111428]/or their processes 
according to their lab SOPs. These data will not be transferred to the trial database. The 
investigator should review such values for AEs and report these according to this protocol.  
• The investigator must review all laboratory results for concomitant illnesses  and AEs.  
• Laboratory samples will be destroyed no later than at finalisation of the CTR.   
• For haematology samples (differential count) where the test result is not normal, then a part 
of the sample may be kept for up to two years or according to local regu lations.   
• Human biosamples for retention will be stored as described in Appendix  6 (Section 10.6). 
Table  10-1 Protocol -required efficacy laboratory assessments  
Laboratory 
assessments  Parameters  
Glucose metabolism  
(V1, V2, V3, V4, V5, 
V6, V6A)  • HbA 1c 
Table  10-2 Protocol -required safety laboratory assessments  
Laboratory  
 assessments  Parameters  
Haematology   
(V1, V6, V6A)  • Erythrocytes  
• Haematocrit  
• Haemoglobin  
• Leucocytes  
• Thrombocytes  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  
Biochemistry1  
(V1, V6, V6A)  • Alanine Aminotr ansferase (ALT)  
• Albumin  
• Alkaline phosphatase  
• Aspartate Aminotransferase (AST)  
• Creatinine  
• Potassium  
• Sodium  
• Total bilirubin  
Lipi[INVESTIGATOR_805]  
(V2, V6, V6A)  • Cholesterol  
• High density lipoprotein (HDL) cholesterol  
• Low density lipoprotein (LDL) cholesterol  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 59 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  60 of 89 
 
   
 • Triglycerides  
• Free fatty acids  
Pregnancy Testing  
(V2, V8)  • Highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)2 
Other tests   • In case of systemic hypersensitivity (see section 8.9.1 ): Tryptase (optimal 0.[ADDRESS_927174] the hypersensitivity reaction), total IgE antibodies, anti -insulin icodec 
IgE antibodies, anti -insulin icodec binding antibodies, anti -human insulin IgE 
antibodies.  
• eGRF calculated by [CONTACT_41162] -EPI [INVESTIGATOR_10908], eGRF is for screening purposes only.  
Notes:  
1Details of required actions for increased liver parameters  are given in Section 10.3 (Hy’s Law).  
2Local urine testing will be standard unless serum testing is required by [CONTACT_18039]/IEC.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 60 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  63 of 89 
 
   
 • All types of acute myocardial infarction and unstable angina pectoris requiring 
hospi[INVESTIGATOR_11956]  
• Cerebrovascular event (stroke or transient ischem ic attack)  
• Epi[INVESTIGATOR_364052], spi[INVESTIGATOR_36232], or retinal vascular injury as a result of haemorrhage or ischemia, with or without 
infarction  
• Heart failure (requiring hospi[INVESTIGATOR_684287])  
• New epi[INVESTIGATOR_111374], unscheduled 
hospi[INVESTIGATOR_111375]/office/emergency department visit  
Adverse events requiring additional data collection  
AEs requiring additional data collection on a specific event form.  
Injection site reaction  
If an event of injection site reaction is observed additional information must be obtained if 
available on a separate form  
Hypersensitivity  
Systemic hypersensitivity can be manifested as isolated symptoms such as urticaria, angioedema, 
conjunctivitis, rhinitis, bronchospasm, gastrointestinal symptoms (nausea, vomiting, diarrhoea, 
abdominal pain), or as anaphylaxis or anaphylactic shock.  
Anaphylaxis is an acute, potentially lethal, multisystem syndrome resulting from the sudden 
release of mast cell - and basophil -derived mediators into the circulation31. It most often results 
from immunologic reactions to foods, medications, and insect stings, although it can also be 
induced through nonimmunologic mechanisms by [CONTACT_111429] a sudden, 
systemic degranulation of mast cells or basophils32. Characteristic symptoms and signs, occurring 
minutes to a few hours after exposure to potential triggering agents or events may include: 
flushing, urticaria, angioedema, hoarseness, throat tightness, stridor, wheezing, coughing, 
shortne ss of breath, abdominal pain, vomiting, and/or hypotension, dizziness or collapse.  
Local hypersensitivity reactions, including rash, redness, pruritus and oedema, may occur at the 
site of investigational drug injection.  
Drug hypersensitivity reactions (DHR s) are the adverse effects of pharmaceutical formulations 
(including active drugs and excipi[INVESTIGATOR_840]) that clinically resemble allergy33. The y can be allergic and 
non-allergic.  
If a hypersensitivity event is suspected, the subjects must contact [CONTACT_684320]. All events of systemic hypersensitivity must be reported, and in case of 
systemic hypersensitiv ity, additional information must be provided on a separate form.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 63 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  69 of 89 
 
   
 10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information  
Definitions  
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.  If fertility is unclear and a menstrual cycle cannot be confirmed before first 
dose of trial treatment, additional evaluation should be considered.  
Females in the following categories are not considered WOCBP  
7. Premenarcheal  
8. Females with one or more of the following:  
• Documented total hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Females with permanent infertility due to an alternate medical cause other than the above (e.g. 
Müllerian agenesis, androgen insensitivity), investigator discretion should be applied in determining 
trial enrolment.  
9. Postmenopausal female:  
• A postmenopausal state is defined as amenorrhoea for 12 months without an alternative 
medical cause.  
• Females  ≥ 50 years of age can be considered postmenopausal (irrespective of treatment with 
a hormonal contraception or hormone replacement therapy (HRT)) if they have both:  
• Amenorrhoea and  
• Documentation of 2 high follicle stimulating hormone (FSH) measurements in  the 
postmenopausal range and one of these was observed ≥1 year prior to screening.  
• Females ≥ [ADDRESS_927175] an acceptable effective contraception methods.  
Note: Documentation regarding categories 1 -3 can come from the site staff’s review of subject’s 
medical records, medical examination or medical history interview.  
Contraception guidance  
Male subjects   
No contraception measures are required as the risk of teratogenicity/fetotoxicity caused by [CONTACT_684321], insulin glargine or insulin degludec in seminal fluid is unlikely34. 
Female subjects  
Female subjects of childbearing potential are eligible to participate if they agree to use at least an 
acceptable  effecti ve method of contraception consistently and correctly as described in Table  10-3 
below. As a minimum, contraception should be maintained until treatment discontinuation.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 69 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  71 of 89 
 
   
 Nordisk within 14 calendar days. Generally, follow -up will not be required for longer than 1 
month beyond the delivery date.  
• Any termination of pregnancy will be reported regardless of the foetal status  (presence or 
absence of anomalies) or indication for procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any adverse event in 
connection with pregnancy or elective termination of a pregnancy for medical reasons will 
be reported as an A E or SAE. If relevant, consider adding “gestational”, “pregnancy related” 
or similar term when reporting the AE/SAE.  
• Pregnancy outcome should be documented in the subject’s medical record. Abnormal 
pregnancy outcome (e.g. spontaneous abortion, foetal death , stillbirth, congenital anomalies 
and ectopic pregnancy) is considered an SAE.  
• AE/SAE in foetus or newborn child can only be reported on paper AE form and SIF and 
should follow the timelines in Figure  10-1. 
• Any SAE occurring as a result of a post -trial pregnancy which is considered 
possible/probably related to the IMP by [CONTACT_684322] 3 (Section 10.3) . While the investigator is not obligated to actively 
seek this information in former subjects, he or she may learn of an SAE through 
spontaneous reporting.  
Figure  10-2 Decision tree for determining the forms to complete with associated timelines 
for pregnancy .  
Maternal form 1b  
  14 calendar days after birthMaternal form 1a
  14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2   14 calendar days
Paternal form*1   14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 10.1.Prior to 
birth or 
pregnancy 
termination For female subjects
 
 
Any female subject who becomes pregnant while participating in the trial will discontinue IMP .  
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 71 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  76 of 89 
 
   
 • A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as wel l as the temporal relationship of the event to trial product administration, will 
be considered and investigated.  
• The investigator will also consult the investigator’s brochure, for marketed products, in 
his/her assessment.  
• For each AE/SAE, the investigato r must  document in the medical records that he/she has 
reviewed the AE/SAE and has provided an assessment of causality for AE or SAE.  
• There may be situations in which an AE/SAE has occurred, and the investigator has minimal 
information to include in the initial report to Novo Nordisk. However, it is very important 
that the investigator always makes an assessment of causality for every event before the 
initial transmission of the SAE data.  
• The investigator may change his/her opi[INVESTIGATOR_684288] o f follow -up information 
and send an AE/SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
 
AE/SAEs should be classified according to four different levels of causality:  
1. Not related  
2. Possible  
3. Probable  
4. Causal relationship  
 
1. Not related: Relationship to the device, comparator or procedures can be excluded when:  
- the event has no temporal relationship with the use of the investigatio nal device, or the 
procedures related to application of the investigational device;  
- the serious adverse event does not follow a known response pattern to the medical 
device (if the response pattern is previously known) and is biologically implausible;  
- the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasible - and reintroduction of its use (or increase 
of the level of activation/exposure), do not impact on the serious adverse event;  
- the event involves a body -site or an organ that cannot be affected by [CONTACT_10398];  
- the serious adverse event can be attributed to another cause (e.g. an underlying or 
concurrent illness/ clinical condition, an effect of another device, drug, trea tment or 
other risk factors);  
- the event does not depend on a false result given by [CONTACT_5749], when applicable;  
In order to establish the non -relatedness, not all the criteria listed above might be met at the same 
time, d epending on the type of device/procedures and the serious adverse event.  
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 76 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927176] terminates, but no longer than 15 years from end of trial after which they will be 
destroyed.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 79 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927177] is recommended to measure PG every 15 
minutes until the PG value is ≥ 3.9 mmol/L (70 mg/dL) and/or symptoms have been resolved in 
accordance with cur rent guidelines.40 
Repeated PG measurem ents and/or symptoms will by [CONTACT_463486][INVESTIGATOR_41106] a succeeding PG value is ≥ 3.9 mmol/L (70 mg/dL) and/or symptoms have been 
resolved and should be reported as only one hypoglycaemic epi[INVESTIGATOR_1865]. In case of several low PG 
values within the hypoglycaemic epi[INVESTIGATOR_1865], the lowest value is the one that will be reported as the PG 
value for the hypoglycaemic epi[INVESTIGATOR_1865], but the start time of the epi[INVESTIGATOR_636140]/or symptom. The remaining value s will be kept as source data.  
If the severity of a hypoglycaemic epi[INVESTIGATOR_111385], only one hypoglycaemic epi[INVESTIGATOR_111386], reflecting the most severe degree of hypoglycaemia.  
Regarding the question: “To feel better, did you need help to get a suga ry drink, food, or 
medicine?” the investigator must instruct the subjects to answer “Yes”, if the epi[INVESTIGATOR_111387], glucagon, or take 
other corrective actions. PG concentrat ions may not be available during an event, but neurological 
recovery following the return of PG to normal is considered sufficient evidence that the event was 
induced by a low PG concentration.[ADDRESS_927178] be re -trained in how to report hypoglycaemic epi[INVESTIGATOR_111389]. The trainin g should be documented by [CONTACT_111438].  
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 81 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  82 of 89 
 
   
 10.9 Appendix 9: Titration guideline  
Introduction  
Titration guidelines have been developed, providing recommended dose adjustments at different PG 
levels to ensure that subjects receive an optimal treatment. However, it is recognised that insulin 
treatment should be individualised, and the specific titration algorithms may not be applicable in 
certain clinical situations. Hence, it is important that other information, such as symp toms of 
hypo -/hyperglycaemia, previous response to dose adjustments, other glucose measurements and 
other indicators of the subject’s level of glycaemic control, is taken into consideration when 
decisions on dosing are made. The investigator is responsible  for the treatment of the subjects and 
can therefore overrule the guidelines to avoid safety hazards.  
Initiation of trial products  
At randomisation eligible subjects will be randomised to receive once weekly insulin icodec or once 
daily basal insulin analo gue, pre -specified by [CONTACT_109481].  
• Insulin icodec  should be taken once weekly on the same day of the week. The starting dose 
should be 70U.  
• Insulin glargine U100 or U300 or Insulin degludec (once daily basal insulin analogues) 
should be t aken once daily in accordance with the locally approved label.  
• There are no maximum or minimum insulin doses.  
Titration of once daily basal insulin analogues  
Titration of once daily basal insulin analogue comparators is at the discretion of the investigator 
according to local clinical practice. The recommended doses for all once daily basal insulin 
analogues will be based on the locally approved label.  
Use of titration assistant applications or other tools is at the discretion of the investigator.  
Titration of insulin icodec  
Titration of insulin icodec should be guided by [CONTACT_684323]. In case of temporary 
suspension of the DoseGuide System, tit ration of insulin icodec can be done in accordance with the 
guidance outlined below.  
Adjustment of insulin icodec will be done in accordance with Table  10-5. 
After randomisation insulin icodec should be considered adjusted once weekly:  
• The dose adjustment will be based on three pre -breakfast SMPG values measured on two 
day prior to titration and on the day of contact.  
• If one or more SMPG values are missing, the dose adjustment should be performed on the 
remaining SMPG value(s)  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 82 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927179] SMPG  Dose adjustment  
Value to use  mmol/L  mg/dL  U 
Lowest of the SMPG 
values  <4.4 <80 –20 
Mean of the SMPG 
values  4.4–7.2 80–130 0 
>7.2 >130  +[ADDRESS_927180] insulin doses is based on all relevant information  
Missing insulin icodec dose guidance  
If an insulin icodec dose is missed for ≤ [ADDRESS_927181] 
the planned dose as soon as possible and perform control SMPG measurement. If the missing dose 
is missed for > [ADDRESS_927182] in how to switch at the 
end of treatment visit (V6).  
Regarding the switch from insulin icodec to post -trial basal insulin the following should be 
considered:  
• Calculate the new daily basal insulin dose dividing the latest insulin icodec dose by 7  
• Initiate the new daily basal insulin  two weeks  after the last injection of insulin icodec  
• Continue to measure pre -breakfast SMPG daily in the follow up period. If pre -breakfast 
SMPG exceeds 10.0 mmol/L (180 mg/dL), it should be considered to initiate the d aily basal 
insulin dose earlier than two weeks after the last dose of insulin icodec  
• Consider titrating the basal insulin once or twice weekly according to the pre -breakfast 
SMPG values and the local label of the chosen insulin.  
Data surveillance  
It is imp ortant that data regarding dose titration is reported in the eDiary  or DoseGuide App (see 
Section 8.2.1 ). 
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 83 89
CONFIDENTIAL
NN1436 -4481  
 Date: 23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  84 of 89 
 
   
 10.10  Appendix 10: Country -specific requ irements   
For Canada  
• Retention of clinical trial documentation: Part C, Division 5 of the Food and Drug 
Regulations [C.05.012] requires a 25 year retention period  
For [LOCATION_013]  
• Demography: Subject’s full Date of Birth is not allowed to be collected and must be 
shortened to Year of Birth in CRF.  
• Contraception requiremen ts: Contraception requirements as per CTFG guideline.  
 
For Hungary  
• Demography: Subject’s full Date of Birth is not allowed to be collected and must be 
shortened to Year of Birth in CRF.  
For Poland  
• Indemnity statement: Novo Nordisk carries liability for the Trial exclusively in the scope 
defined by [CONTACT_684324] 6 September 2001 (uniform version Journal of Laws of 2008 No. 45 item 271 
with amendme nts). In order to support potential claims for liability attributable to the Trial, 
Novo Nordisk and Investigator are covered by [CONTACT_111443].  
For Turkey  
• Blood samples from Turkey will be analysed by a ce ntral lab.  
• This is a phase 3 trial  
For [LOCATION_003]  
• Retention of clinical trial documentation: 15 years  
• Financial disclosure:  Verification under disclosures per Code of Federal Regulations 
(CFR) of Financial Conflict of Interest.  
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 84 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  85 of 89 
 
   
 10.11  Appendix 11: Abbreviations  
AE adverse event  
ALT  alanine aminotransferase  
ASADE  anticipated serious adverse device effect  
AST  aspartate aminotransferase  
BG blood glucose  
CRF  case report form  
CTR  clinical trial report  
DFU  directions for use  
DMC  data monitoring committee  
DRE  disease related event  
DUN  dispensing unit number  
EAC  event adjudication committee  
ECG  electrocardiogram  
eCRF  electronic case report form  
FAS full analysis set  
FDA  U.S. Food and Drug Administration  
FDAAA  FDA Amendments Act  
FPG fasting plasma glucose  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
HbA 1c glycated haemoglobin  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IMP investigational medicinal product  
IRB institutional review board  
IWRS  interactive web response system  
LDL  low-density lipoprotein  
LSLV  last subject last visit  
MIDF  monitor -initiated discrepancy form  
NIMP  non-investigational medical product  
PCD  primary completion date  
PG plasma glucose  
PRO  patient reported outcome  
RNA  ribonucleic acid  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 85 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927183]  
WOCBP  woman of child bearing potential  
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 86 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  87 of 89 
 
   
 11 References  
1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes:. Diabetes Care. 
2019;42(Suppl 1):S13 -S28. 
2. International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. 2019.  
3. Alatorre C, Fernández Landó L, Yu M, Brown K, Montejano L, Juneau P, et al. Treatment 
patterns in patients with type 2 diabetes mellitus treated with glucagon -like peptide -1 
receptor agonists: Higher adherence and persistence with dulaglutide compared with once -
weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19(7):953 -61. 
4. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2 005;36(3):197 -209. 
5. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 
2004;88(4):787 -835, ix.  
6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. 
Management of hyperglycaemia in type 2 diabetes, 2015: a patient -centred approach. 
Update to a position statement of the American Diabetes Association and the European 
Association for the Study of Diabetes. Diabetologia. 2015;58(3):429 -42. 
7. European Medicines Agency. Guideline on clinical investigation of me dicinal products in 
the treatment or prevention of diabetes mellitus (CPMP/EWP/1080/00 Rev. 1). 14 May 
2012.  
8. Halimi S, Balkau B. Better analyze the determinants of therapeutic inertia to overcome it. 
Diabetes Metab. 2012;[ADDRESS_927184] 3:S27 -8. 
9. Khunti K, M illar-Jones D. Clinical inertia to insulin initiation and intensification in the [LOCATION_006]: 
A focused literature review. Prim Care Diabetes. 2017;11(1):3 -12. 
10. Novo Nordisk A/S. Investigator's Brochure, insulin icodec, project NN1436, (edition 6). 3 
Jun 2020.  
11. Novo Nordisk A/S. Investigator’s Brochure, DoseGuide System, project DH3417 (edition 
1),. 12 Nov 2020.  
12. International Organization for Standardization. EN ISO [ZIP_CODE]:2020, Clinical investigation 
of medical devices for human subjects - Good clinical pr actice. Jul 2020.  
13. Novo Nordisk A/S. Investigator's Brochure, Insulin Degludec (Tresiba®), project : NN1250 
IDeg, (edition 15). 2018.  
14. Novo Nordisk A/S. Tresiba® (insulin degludec)  EU Summary of Product Characteristics 
(SmPC). 12 Nov 2018.  
15. Novo Nordisk A/S. Tresiba® (insulin degludec), US Prescribing Information (PI). Mar 2018.  
16. GmbH S -AD. Lantus® (insulin glargine), EU Summary of Product  Characteristics (SmPC). 
16/03/2020 2020.  
17. [COMPANY_011] -Aventis US. SoliquaTM 100/33 (insulin glargine/lixisenatide), US Prescribing 
Information. Nov 2016.  
18. Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once -weekly 
medications for diabetes. Diabetes Obesity & Metabolism. 2011;13(2):144 -9. 
19. Food and Drug Administr ation, CDER. Guidance for Industry. Diabetes Mellitus: 
Developi[INVESTIGATOR_111391], Draft Guidance. 
February 2008.  
20. Russell -Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs 
insulin  glargine and placebo in combination with metformin and sulfonylurea therapy in 
type 2 diabetes mellitus (LEAD -5 met+SU): a randomised controlled trial. Diabetologia. 
2009;52(10):2046 -55. 
21. Little R, Rubin D. Statistical analysis with missing data. Sons.  JW, editor. [LOCATION_001].: John 
Wiley & Sons. 1987.  
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 87 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  [ADDRESS_927185] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.  
23. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2),  Step 4 
version. 09 Nov 2016.  
24. International Organization for Standardization. EN ISO [ZIP_CODE]:2011, Clinical investigation 
of medical devices for human subjects - Good cl inical practice. 2011.  
25. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351(12):[ADDRESS_927186] of 2007 as amended by [CONTACT_43679] "Clinical 
Trials Registration and Results Information Submission". 21 September 2016.  
27. The European Parliament an d the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_927187] of clinical trials on medicinal 
products for human use. 2001.  
28. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004  laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.  
29. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 December 2006 on 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726 /2004, article 41. 
Official Journal of the European Communities. [ADDRESS_927188], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version  
available at www.icmje.org . 
31. Sampson HA, Munoz -Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report --
Second National Institute of Allergy and Infectious Dis ease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol. 2006;117(2):391 -7. 
32. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin 
Immunol. 2002;110(3):341 -8. 
33. Johansson SG, Bieber T, Dahl R, Friedmann  PS, Lanier BQ, Lockey RF, et al. Revised 
nomenclature for allergy for global use: Report of the Nomenclature Review Committee of 
the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832 -6. 
34. Scialli AR, Bailey G, Beyer BK, B øgh IB, Breslin WJ, Chen CL, et al. Potential seminal 
transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58:213 -21. 
35. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 
mmol/L (54 mg/dL) Should Be Reported i n Clinical Trials: A Joint Position Statement of 
the American Diabetes Association and the European Association for the Study of Diabetes. 
Diabetes Care. 2017;40(1):155 -7. 
36. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in  
Diabetes -2018. Diabetes Care. 2018;41(Suppl 1):S55 -S64. 
37. Abraham MB, Jones TW, Naranjo D, Karges B, Oduwole A, Tauschmann M, et al. ISPAD 
Clinical Practice Consensus Guidelines 2018: Assessment and management of 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 88 89
CONFIDENTIAL
NN1436 -4481  
 Date:  23 November 2020  Novo Nordisk  
Protocol  Version:  2.0 
      Status:  Final  
      Page:  89 of 89 
 
   
 hypoglycemia in children and adolescents  with diabetes. Pediatr Diabetes. 2018;[ADDRESS_927189] 
27:178 -92. 
38. Agiostratidou G, Anhalt H, Ball D, Blonde L, Gourgari E, Harriman KN, et al. 
Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 
Diabetes: A Consensus Report of the Ame rican Association of Clinical Endocrinologists, 
the American Association of Diabetes Educators, the American Diabetes Association, the 
Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable 
Trust, the Pediatric Endocrine Socie ty, and the T1D Exchange. Diabetes Care. 
2017;40(12):1622 -30. 
39. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International 
Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):[ADDRESS_927190] ER, Anderson J, Childs B, Cryer P, Dagogo -Jack S, Fish L, et al. Hypoglycemia 
and diabetes: a report of a workgroup of the American Diabetes Association and the 
Endocrine Society. Diabetes Care. 2013;36(5):1384 -95. 
 
 
 
 
NN1436-4481 NN1436 0  | VV-TMF-[ZIP_CODE]  . -  | 2
 |  of   Protocol  Protocol V2.0 89 89
CONFIDENTIAL